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Abstract 
Osteoarthritis (OA) is the most common joint disease and a major cause of physical 
disability, however no disease modifying treatments are available. To better understand the 
molecular mechanisms involved, my colleagues previously performed microarray studies on 
a surgical rodent model of OA. Transforming growth factor alpha (TGFα) was identified as a 
novel growth factor involved in cartilage degeneration and subsequent experiments revealed 
that it induced an OA-like phenotype in articular chondrocytes. These findings lead to the 
overarching hypothesis for my thesis: TGFα promotes OA.  
I began by studying TGFα’s interaction with endothelin receptor A (ET(A)R) as this 
signaling system is known to be involved in both aging and OA. I used in vitro cultures to 
examine whether TGFα-effects were regulated by this pathway and found that TGFα 
induced expression of ET(A)R at both the gene and protein level. By inhibiting ET(A)R, I 
was able to partially block some deleterious TGFα effects, however, it was evident that 
additional downstream targets were involved in TGFα signaling.   
To examine the role of TGFα in vivo, I used the Tgfa null mouse. I first examined bone 
development as developmental events are often recapitulated in disease. Tgfa null mice had a 
transient growth plate phenotype characterized by an expanded hypertrophic zone and a 
delay in the transition from cartilage to bone. I also observed a decrease in RANKL and 
MMP13 gene expression as well as fewer osteoclasts as the cartilage/bone junction. These 
data suggest that decreased matrix resorption is responsible for the persistence of the 
hypertrophic zone. 
 iv 
 
Lastly, I examined post-traumatic and aging OA models. Interestingly, I found that young 
adult Tgfa null mice were protected from developing OA in the traumatic model, however 
they were not protected with age. These data suggest that TGFα might be more relevant as a 
therapeutic target in post-traumatic subtypes of OA but not necessarily in idiopathic disease. 
Overall, these data demonstrate a novel role for TGFα in both bone development and OA. 
My developmental and disease data support my hypothesis, as TGFα appears to be a major 
regulator of cartilage catabolism in both systems.  
Keywords 
Transforming growth factor alpha, osteoarthritis, articular cartilage, endothelin receptor A, 
endochondral ossification, osteoclasts, MMP13, Rankl, DMM 
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Chapter 1  
1 Literature Review 
1.1 Skeletal Development  
The skeleton distinguishes vertebrate species from invertebrate ones. It is formed from 
two tissues types: cartilage (produced by chondrocytes) and bone (produced by 
osteoblasts) (98). Both chondrocytes and osteoblasts are derived from a common 
mesenchymal precursor referred to as the osteochondroprogenitor. There are two main 
processes through which bone development occurs: endochondral ossification and 
intramembranous ossification (59). Both processes begin with the recruitment of 
mesenchymal precursor cells to the location where the future bone will develop (40). 
Next, the mesenchymal cells form condensations via adhesion molecules and form the 
template that will eventually be replaced by bone (40).  
1.1.1 Intramembranous Ossification 
Intramembranous ossification occurs in several areas of the body including the flat bones 
of the skull (59). During this process, the condensations of mesenchymal precursor cells 
differentiate directly into osteoblasts and subsequently produce bone matrix (59). Runx2 
and Osx (osterix) are two transcription factors that are absolutely essential for 
osteoblastogenesis as mice with null mutations for either of these genes lack osteoblasts 
(74). Most bones in the body do not form directly from osteoblasts however, but rather 
form through a cartilage intermediate during the process of endochondral ossification.  
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1.1.2 Endochondral Ossification  
Endochondral ossification is the process through which the long bones of the body grow 
and develop. As opposed to intramembranous ossification, cells within the mesenchymal 
condensations differentiate into chondrocytes and form a cartilaginous template that will 
eventually be replaced by bone (59).  Chondrogenesis itself is regulated by a number of 
transcription factors, one of most important being Sox9 (sex reversal Y-related high-
mobility group box protein) (57). Sox9 directly regulates a number of genes critical for 
chondrocyte function including Col2a1 (type II collagen) and Agc1 (aggrecan) (57). It is 
also necessary for the formation of mesenchymal condensations, the expression of Runx2, 
the expression of other Sox family members, as well as chondrocyte differentiation and 
proliferation (4, 57). 
Endochondral ossification continues when cells at the periphery of the cartilage template 
become flattened, producing a boarder of perichondrium (12, 59). The perichondral cells 
retain the ability to differentiate into either osteoblasts or chondrocytes (61).  Next, 
driven by Sox9, cells in the center of the template begin to proliferate and produce a 
characteristic matrix composed of type II collagen and aggrecan (12, 59). Eventually cells 
near the center of the template stop proliferating and undergo hypertrophy (12, 59). This 
step of terminal differentiation is controlled by several transcription factors including 
Runx2 (57). The hypertrophic chondrocytes are unique in that they produce a matrix 
predominantly containing type X collagen and promote vascular invasion through 
secretion of vascular endothelial growth factor (VEGF) (12, 59). They also signal to 
adjacent perichondral cells through Indian hedgehog (Ihh), causing them to differentiate 
into osteoblasts and form the bone collar (12).  After they have secreted their matrix, 
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hypertrophic chondrocytes undergo apoptosis and the blood vessels they attracted provide 
osteoclasts and osteoblasts precursors that will resorb the hypertrophic matrix and lay 
down true bone (12, 59, 70). The invading blood vessels require the help of degradative 
enzymes such as matrix metalloproteinases 13 and 9 (MMP13 and MMP9) to break down 
the horizontal septa of matrix (70). The vertical septa of cartilage matrix between rows of 
terminal chondrocytes serve as a scaffold for the formation of this true bone (also known 
as the primary spongiosa) (12, 59, 70). Over time, this primary bone will be remodeled to 
secondary trabecular bone (12). Collectively, this area of activity at the center of the 
cartilage template is referred to as the primary ossification center (59).  
1.1.3 Cartilage Growth Plate 
During endochondral bone growth, the chondrocytes become highly organized into 
distinct zones with separate functions (Figure 1.1). The chondrocytes closest to the ends 
of the bones are small, rounded, and relatively quiescent and are referred to as resting 
cells (12, 59, 70). Below them, rapidly dividing chondrocytes form columns of flat, coin-
shaped proliferating cells and secrete type II collagen and aggrecan (12, 59, 70). When 
proliferating chondrocytes exit the cell cycle, they first become pre-hypertrophic, then 
terminally differentiate into hypertrophic chondrocytes. As stated above, these cells 
secrete a matrix rich in type X collagen that will eventually be resorbed and replaced with 
true bone (12, 59, 70). Hypertrophic chondrocytes are easily distinguishable 
histologically due to their significantly increased volume (12). Collectively, this 
organizational arrangement is referred to as the cartilage growth plate and one growth 
plate is present on either end of a developing long bone.  
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Figure 1.1 The zones of the cartilage growth plate. The cartilage growth plate is highly 
organized with several distinct zones. The resting zone consists of small, round, and 
relatively quiescent cells near the ends of the bone. Next is the proliferating zone, which 
consists of stacks of flattened, coined-shaped cells. Once these cells stop proliferating, 
they enlarge, becoming prehypertrophic before they terminally differentiate into 
hypertrophic chondrocytes.  
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1.1.4 PTHrP/Ihh Signaling 
Bone development and growth are tightly regulated by both local factors such as 
fibroblast growth factors (FGFs) and bone morphogenetic proteins (BMPs) as well as 
systemic factors such as growth hormone, thyroid hormone, and vitamin D (59, 70). The 
parathyroid hormone related peptide (PTHrP) and Indian hedgehog (Ihh) signaling 
pathway is an example of the tight control and coordination that is involved within the 
cartilage growth plate (59). During bone development, perichondral cells at the ends of 
cartilage template produce PTHrP. The PTHrP receptor (PTH/PTHrP receptor) is a G-
protein coupled receptor found on the cell surface of chondrocytes, particularly pre-
hypertrophic chondrocytes and those in the lower proliferating zone (12, 60). When 
activated, the receptor signals to increase SOX9 activity and reduce RUNX2 mRNA and 
protein, thus maintaining chondrocyte proliferation and inhibition the transition to 
terminal differentiation (60). Once chondrocytes do stop proliferating, however, they 
secrete Ihh (Indian hedgehog), which has several roles. Ihh signals to the adjacent 
perichondral cells and causes them to differentiate into osteoblasts. It also increases the 
synthesis of PTHrP, to accelerate the differentiation of round proliferating cells to flat, 
coin-shaped proliferating cells, and increases the rate of proliferation in adjacent 
chondrocytes (59-61).   
1.1.5 Secondary Ossification Centre 
As long bones continue to grow, secondary ossification centers form at the proximal and 
distal ends. These additional ossifications centers form through a similar process as 
described above: chondrocytes stop proliferating, terminally differentiate, and attract 
blood vessels that will subsequently lay down new bone (59). The cartilage at the very 
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ends of bones becomes known as articular cartilage and its main function is to provide 
smooth movements for diarthrodial joints. 
1.1.6 Growth Plate Closure 
Longitudinal growth declines as the skeleton reaches maturity. Changes in the growth 
plate occur, such as decreased proliferation, decreased diameter of the hypertrophic 
chondrocytes, and decreased cell density (11). In humans, the growth plate closes 
following puberty and this process is primarily under the control of the sex hormone 
estrogen (11). 
1.2 The Skeleton 
The human skeleton is a complex and dynamic structure comprised of over 200 
individual elements (51). It provides support and protection for vital organs and bone 
marrow, as well as attachment sites for muscles thus facilitating movement (39, 51). 
Bone also has important metabolic functions as it serves as the main reservoir for calcium 
and phosphate in the body (39). Throughout life, bone constantly remodels and repairs 
itself thorough the coordinated activities of osteoblasts and osteoclasts, which together 
are referred to as the basic multicellular unit (BMU) (39, 83). 
1.2.1 Bone Matrix 
Bone is a porous material containing blood vessels, cells, and a mineralized extracellular 
matrix. The matrix itself is primarily composed of type I collagen fibers, calcium 
containing hydroxyapatite crystals, and non-collagenous proteins such as osteocalcin 
(39). There are two main types of bone found within the skeleton: cortical and trabecular 
(39). Cortical bone is very dense, has a low turnover rate, and makes up approximately 
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eighty percent of the skeleton (39). It is located on the outer surfaces of skeletal elements 
providing strength and protection. Trabecular bone comprises the remaining twenty 
percent of the skeleton by mass, but it makes up eighty percent of the skeleton by volume 
(39). Trabecular bone is found within the long bones of the skeleton, and in the inner 
portions of other bones including the vertebral bodies and the bones of the pelvis (39). In 
contrast to cortical bone, trabecular bone is less dense and has a high turnover rate, thus 
making it the primary source for metabolic responses (39). 
1.2.2 Bone Remodeling 
Bone remodeling occurs constantly throughout life as the skeleton responds to 
mechanical loads and strains and repairs microfractures (39). The two cell types 
responsible for this process are the bone-resorbing osteoclasts and the bone-forming 
osteoblasts, which together are known as the basic multicellular unit (BMU). These two 
cell types communicate and collaborate to carry out the three major stages of bone 
remodeling: resorption, reversal, and formation (39, 92).  
1.2.3 Osteoclasts 
Osteoclasts are derived from hematopoietic stem cells (27, 57). Binding of RANKL 
(receptor activator of nuclear factor kappa B ligand) to its receptors on pre-osteoclasts 
causes their activation, fusion, and differentiation to mature multinucleated cells (27, 39). 
Osteoclasts are equipped with abundant mitochondria and lysosomal enzymes that enable 
them to carry out their bone-resorbing function (27, 39). The surface of the osteoclast in 
contact with bone matrix is called the ruffled boarder, and it is along this surface that 
osteoclasts release their digestive enzymes including tartrate resistant acid phosphatase 
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(TRAP), cathepsin K, and MMP9 (27, 39). In addition to proteolytic enzymes, osteoclasts 
release hydrogen ions to acidify the matrix, thus releasing inorganic components (27, 39).  
1.2.4 Osteoblasts 
Unlike osteoclasts, osteoblasts are derived from mesenchymal stem cells and their 
differentiation is dependent on the master regulator gene Runx2 (runt-related transcription 
factor 2) (57). Osteoblasts are found in clusters along the bone surface where they deposit 
type I collagen along with other non-collagenous proteins including osteocalcin, 
osteopontin, osteonection, bone sialoprotein, biglycan, and decorin (27, 39). Collectively, 
this unmineralized matrix is termed osteoid, and it will eventually become mineralized 
with the deposition of hydroxyapatite crystals (27, 39). Osteoblasts are also responsible 
for regulating osteoclast differentiation through the RANKL/OPG (osteoprotegerin) 
signaling axis (27). 
1.2.5 RANKL/OPG Signaling Axis 
RANKL is a peptide expressed on the surface of preosteoblasts and stromal cells (39). It 
is a member of the TNF superfamily and in addition to cell surface expression, it can be 
cleaved to a soluble form (27, 39, 92).  Its receptor, RANK, is located on the surface of 
osteoclast precursor cells and when activated, initiates osteoclast differentiation and 
activation (39, 92).  RANKL is absolutely required for osteoclastogenesis as mice lacking 
RANKL fail to produce osteoclasts (75). Cells of the osteoblast lineage also produce a 
soluble decoy receptor, OPG that binds to RANKL, inhibiting its ability to activate 
RANK (27, 39, 92). This coupling of osteoclast and osteoblast activity produces an 
efficient and coordinated process of bone remodeling.   
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1.3 Articular Cartilage 
1.3.1 Cartilage Classification 
Cartilage is a type of connective tissue found throughout the body with various roles 
depending on its location and subtype. There are three major histological classifications 
of cartilage based on the predominant structural components of the extracellular matrix: 
elastic, fibro-, and hyaline cartilage (22). Elastic cartilage is located in the epiglottis and 
eustachian tube, and as the name suggest, contains a high proportion of elastic fibers (22).  
Fibrocartilage is found in the intervertebral discs of the spine as well as the menisci of the 
knee joints and has a high proportion of fibrous tissue rich in type I collagen fibers (22, 
81). Hyaline cartilage forms the growth plate of long bones and provides a template that 
will eventually be replaced by bone. Hyaline cartilage is also found at the ends of 
diarthrodial joints forming articular cartilage, and its predominant matrix component is 
type II collagen (22, 81).  
1.3.2 Articular Cartilage Composition 
Articular cartilage is the highly specialized tissue that covers joint surfaces, giving rise to 
near frictionless, wear-resistant and efficient movements. There are two main 
components of articular cartilage: the chondrocytes (the cells of articular cartilage) and 
the extracellular matrix in which they reside. Articular cartilage is relatively acellular 
compared to other tissues in the body, with chondrocytes comprising only about two 
percent of the total cartilage volume in adults (81). Articular cartilage is avascular, 
aneural, and alymphatic, and consequently the chondrocytes themselves are primarily 
responsible for secreting components of the extracellular matrix and for regulating much 
of its turnover (3). The vast majority of articular cartilage is comprised of the 
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extracellular matrix which is rich in type II collagen, proteoglycans such as aggrecan, 
hyaluronic acid, and cross-linking proteins (3). Articular cartilage is a dynamic tissue as 
type II collagen provides the main structural network and tensile strength while aggrecan 
attracts water providing elastic properties (3). Due to the low cell density and lack of 
blood supply however, articular cartilage is limited in its ability to self-repair. 
1.3.3 Zonal Organization 
Articular cartilage is designed to absorb and distribute the various stresses experienced 
during joint loading (55, 81). It can be divided into three major zones (superficial, 
middle, and deep), each with its own unique cellular distribution and extracellular matrix 
arrangement (Figure 1.2). The superficial zone is relatively thin, and contains 
horizontally arranged collagen fibrils in parallel with the articular surface (55). The 
chondrocytes in the superficial zone are elliptical in shape and are also found parallel to 
the surface (55). These chondrocytes synthesize and secrete a protein called lubricin, 
which as the name implies, helps to lubricate and maintain a smooth, frictionless 
articulating surface (81). In addition, the superficial zone is crucial to the function of 
articular cartilage as it is able to withstand tensile forces experienced during joint loading 
(81). In the middle zone, chondrocytes are spherical in shape and are surrounded by 
randomly distributed collagen fibrils (55). Proteoglycan content increases in the midzone, 
and continues to increase as one moves deeper within the articular cartilage layers (81). 
This is important because aggregating proteoglycans attract water molecules and provide 
articular cartilage with its elastic properties (3). Proteoglycan aggregates form when 
aggrecan monomers attach to a hyaluronic acid backbone via link protein (55, 81). These  
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Figure 1.2 The zones of articular cartilage. The function of articular cartilage is 
dependent on its zonal organization. The superficial zone consists of elongated 
chondrocytes situated in parallel with the articular surface. Collagen fibrils in this zone 
are also parallel to the surface. Next is the middle zone, which is characterized by 
spherical chondrocytes surrounded by more randomly distributed collagen fibrils.  
Beyond this lays the deep zone containing columns of chondrocytes surrounded by 
collagen fibrils perpendicular to the surface. The tidemark divides the articular cartilage 
from the calcified cartilage below. 
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Figure 1.2 The zones of articular cartilage. 
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monomers are composed of a protein core to which negatively charged 
glycosaminoglycans (GAGs) such as chondroitin sulfate and keratan sulfate attach (55).  
The negatively charged molecules attract and bind intercellular water which can be 
essentially ‘squished out’ under compressive forces, and drawn back in after the joint has 
been unloaded (3). Lastly, the deep zone contains large chondrocytes arranged in 
columns and collagen fibrils here are found perpendicular to the articular surface (55). 
Between the deep zone and the subchondral bone exists a layer of calcified cartilage 
which contains very large chondrocytes that behave similarly to the hypertrophic 
chondrocytes of the cartilage growth plate (81). These chondrocytes secrete type X 
collagen that can subsequently be mineralized. The ‘tidemark’ is a histologically visible 
line demarcating the articular cartilage from the underlying calcified cartilage. The 
calcified cartilage is believed to provide a transition zone from cartilage to subchondral 
bone (81).  
1.3.4 Regional Organization 
In addition to the zonal organization of the articular cartilage, the extracellular matrix is 
also described based on its proximity to the chondrocytes themselves (3). The matrix 
directly adjacent to the chondrocytes is called the pericellular matrix and is rich in type 
VI collagen and proteoglycans (36). The interterritorial matrix occupies the largest 
proportion of articular cartilage and refers to the matrix farthest from the chondrocytes 
(36). As mentioned, this proportion of the matrix is comprised primarily of type II 
collagen, aggrecan, and water and allows the cartilage to deal with compressive forces. 
The cartilage between the pericellular and interterritorial matrix is referred to as the 
territorial matrix, but currently has no specific characterization (3). 
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1.3.5 Cell-Matrix Interactions 
Chondrocytes are in physical contact with their pericellular environment through cell 
surface receptors such as CD44 and integrins that directly bind matrix molecules (36). 
These cell surface receptors provide a direct means through which chondrocytes can 
interact with and to respond to their extracellular environment and mechanical stimuli. In 
addition, articular chondrocytes express stretch-activated calcium channels that respond 
to mechanical stimuli by modulating intracellular calcium waves. These fluxes in calcium 
subsequently cause the release of growth factors and cytokines that can then signal in an 
autocrine and/or paracrine manner (2, 23). Finally, the chondrocyte cytoskeleton appears 
to play an important role in mediating cellular events. In all cell types, the cytoskeleton 
serves as the load-bearing architecture of the cell and can be altered by various forces (5). 
Several studies have indicated that disruption of the actin cytoskeleton causes 
chondrocyte de-differentiation to a fibroblastic-like phenotype (16).  
1.3.6 Extracellular Matrix Metabolism 
Articular chondrocytes exist in an avascular, relatively hypoxic environment (33, 35). 
Consequently, they are relatively metabolically inactive and have a low regenerative 
capacity. Glucose is their main energy source and enters the cells via facilitated transport 
(33). Glucose also serves as a precursor for the intracellular production of 
glycosaminoglycans (GAGs) (33).  Adult articular cartilage has a low turn over rate with 
the half-life of collagen being about one hundred years and the half-life of aggrecan core 
protein fractions ranging from three to twenty-four years (33).  Matrix metabolism may 
however be accelerated in the pericellular zone and may also vary in disease states. 
Anabolic factors including transforming growth factor beta (TGFβ) and insulin-like 
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growth factor-1 (IGF-1) stimulate extracellular matrix (ECM) synthesis by chondrocytes 
(87). Conversely, inflammatory cytokines such as interleukin-1 beta (IL-1β) and tumor 
necrosis factor alpha (TNFα) stimulate catabolic factors (i.e. matrix metalloproteinases) 
and are thus associated with matrix destruction (87). In healthy cartilage there is an 
overall balance between matrix synthesis and degradation (3).  In the disease state of 
osteoarthritis (OA) however, the balance is shifted in favour of degradation leading to 
subsequent joint dysfunction.  
1.4 Osteoarthritis 
Osteoarthritis (OA) is a chronic degenerative joint disease characterized by joint pain, 
stiffness, and eventual loss of function (93). It is the most common joint disease 
worldwide and the leading cause of physical disability in industrialized nations (58, 86). 
It has been reported that one in four people in their sixties and more than half of all 
people over the age of eighty demonstrate radiographic signs of OA (24). Furthermore, 
sixty-seven percent of women and fifty-five percent of men over the age of fifty-five 
have OA of the hand (14). While advanced age is a significant risk factor for the 
development of the disease, OA can be seen in all age groups (17). Individuals living 
with OA experience a substantial decline in their health-related quality of life compared 
to individuals without the disease (85, 97). They suffer most dramatically physically, but 
also mentally, and socially (97) . Furthermore, unlike rheumatoid arthritis, no disease 
modifying drugs are available for OA. Therefore, most treatments are long term and are 
limited to managing symptoms (102). The immense costs associated with OA are both 
direct (medications, hospitalizations) and indirect (loss of work and productivity) and 
place a significant burden on our health care system and economy (15, 100). Due to the 
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prevalence of OA and the disability caused by it, OA poses significant socioeconomic 
challenges. 
1.4.1 Etiology and Risk Factors 
While OA can present in any joint in the body, it is most commonly found in the weight 
bearing joints of the knees and hips as well as in the small joints of the hands (in 
particular the distal interphalangeal joints) and the spine (17, 93).  Although the exact 
etiology of OA remains elusive, it appears to be multifactorial in nature with many 
identifiable risk factors. For example, there is good evidence to show that in addition to 
increasing age, female gender, obesity, joint injury, joint malalignment, and occupations 
involving repetitive joint loading all contribute the development of OA (17, 104). As 
well, genetics play a clear role (86, 96). Twin studies have reveal concordance rates of 
60% for hip OA and 39% for knee OA based on radiological findings in identical female 
twins (96). These data are independent of environmental factors. Several gene mutations 
are associated with OA, some of which encode articular cartilage matrix proteins 
including type II collagen (86). Other disease associated genes are expressed in bone, 
skeletal muscle, the cartilage growth plate, or in multiple synovial joint tissues (86). In 
reality, it is likely that genetic factors give rise to a predisposition for OA but that the 
mechanical and other risk factors also contribute to disease onset and progression. 
1.4.2 Classification 
OA can broadly be classified into two main groups: 1) primary or idiopathic and 2) 
secondary or post-traumatic (17). Primary OA refers to a disease without a definite 
etiologic cause. It is possible, however, that individuals have an unknown genetic 
predisposition. Primary OA is rarely found in individuals under the age of 40 (17).  
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Secondary OA, on the other hand, refers to a disease state in which there is a definite 
event or abnormality leading to joint degeneration. For example, joint injuries (i.e. 
ligament or meniscal tears), intra-articular fractures, and congenital abnormalities (i.e. hip 
dysplasia) can all result in joint degeneration (6, 17, 104). Unlike primary OA, secondary 
OA is often found in younger individuals. Regardless of the classification, both forms of 
OA are complex, multivariable, and affect the entire joint. While rates of progression 
may be variable, subsequent disease sequelae are often indistinguishable and involve 
joint pain, stiffness, and loss of function (17). 
1.4.3 A Disease of the Synovial Joint 
While degeneration of articular cartilage is the hallmark of OA, it is important to 
remember that the disease actually affects the entire synovial joint. In addition to 
progressive cartilage damage, an osteoarthritic joint often involves subchondral bone 
sclerosis, synovitis (inflammation of the synovial membrane), and osteophyte formation 
(bony outgrowths at the joint margin) (3, 47) (Figure 1.3).  
1.4.3.1 Articular Cartilage 
While articular cartilage degeneration is the defining feature of OA, a number of more 
subtle changes also occur within the extracellular matrix and the chondrocytes 
themselves. Cartilage degeneration often begins with fibrillations at the articular surface 
which eventually penetrate into the deeper zones (80). Another early sign of osteoarthritis 
is chondrocyte proliferation resulting in clustering of cells (34, 87). Early proliferation 
may be a consequence of early cartilage damage that subsequently allows mitogenic 
factors from other tissues such as the synovium to reach the chondrocytes (86).  
Chondrocytes may also de-differentiate and lose their characteristic phenotype of type II 
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collagen and aggrecan expression (78, 87). Other chondrocyte changes that have been 
observed are hypertrophy, apoptosis, and autophagy although their actual contribution to 
OA pathology is not quite clear (13, 87). These processes, like osteophyte formation, are 
reminiscent of stages in endochondral bone development. 
1.4.3.2 Synovium 
The synovial membrane lines the joint capsule and contains an inner layer of 
metabolically active cells called synoviocytes (3). The synoviocytes help to nourish the 
avascular articular cartilage, remove cartilage breakdown products from joint space, and 
produce synovial fluid proteins including lubricin and hyaluronic acid (3, 91). The 
proteins help to lubricate the joint and reduce friction, thus protecting the articular 
cartilage (91). Histological changes observed in OA can be seen in both early and late 
stages of the disease and include synovial cell hyperplasia, inflammation (involving the 
invasion of leukocytes), and capsular fibrosis (58, 91). The synoviocytes can also 
contribute directly to cartilage degeneration via production of inflammatory cytokines 
and catabolic enzymes (91). 
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Figure 1.3 A schematic representation of a healthy and osteoarthritic joint. 
Osteoarthritis (OA) is a disease that affects the entire joint. Components of the synovial 
joint include articular cartilage (blue), the joint capsule (light pink), the synovium (lining 
the joint capsule), and the subchondral bone (areas directly beneath the articular 
cartilage). Features of OA are depicted on the right side of the joint and include 
degradation of articular cartilage, inflammation of the synovium, osteophyte formation, 
and subchondral bone sclerosis (dark grey). 
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Figure 1.3 A schematic representation of a healthy and osteoarthritic joint. 
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1.4.3.3 Subchondral Bone 
OA is associated with increased subchondral bone remodeling and thickness, however 
there is uncertainty as to whether this occurs in response to the disease process or 
whether this is perhaps a causative factor (21, 65). Osteoarthritic subchondral bone is 
associated with increased osteoblast activity and increased osteoid deposition (64). The 
increase in bone volume however, is associated with abnormal collagen fibrils and 
decreased mineralization (65). Animal studies have indicated that increased bone 
turnover and subsequent subchondral bone thickening are predictive of OA development, 
thus suggesting that bone changes precede cartilage damage (19). In addition to these 
subchondral bone changes, reactivation of the secondary ossification centre causes 
advancement of the cartilage tidemark in OA, effectively thinning the articular cartilage 
(19, 21). Together subchondral bone sclerosis and the advancing tidemark alter the 
mechanics of the joint and may potentially exacerbate cartilage damage (19, 21). 
1.4.3.4 Osteophytes 
Osteophytes are yet another bone-related abnormality found in osteoarthritis. These bony 
outgrowths form through an endochondral process and may be an attempt to restore 
stability to a degenerating joint (80, 87). In actuality, however, they may interfere with 
joint function and mobility. The origin of the osteophytes is uncertain, but they may be 
derived from undifferentiated cells of the perichondrium (87). The stages of osteophyte 
development (differentiation, proliferation, hypertrophy) are similar to those observed 
during endochondral bone growth (87).  
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1.4.4 Diagnosis  
Often patients with OA present to their physicians complaining of joint pain as this is the 
most prevalent symptom of the disease (93). The diagnosis of OA can be made clinically 
with a medical history and physical exam (44, 93). No specific tests are required. X-ray is 
a simple imaging technique that can be used to confirm the diagnosis and reveal the 
cardinal signs of OA: asymmetric joint space narrowing, the presence of osteophytes 
(bony outgrowths), subchondral bone sclerosis, and subchondral cysts (44). The joint 
space narrowing represents loss of articular cartilage at the ends of bones, thus reducing 
the space between bones. It is important to note that clinical and radiographic findings do 
not always match and thus lack of radiographic evidence should not exclude the 
diagnosis of OA (42, 44). Furthermore, if one has radiographic changes consistent with 
OA but does not experience any symptoms, a diagnosis is not warranted. The limitation 
of these diagnoses is that patients are often identified very late in the disease course.   
1.4.5 Treatment 
Currently there is no cure for OA and unlike rheumatoid arthritis, no disease modifying 
drugs are available to alter the course of the disease. Consequently, treatment options are 
limited to managing symptoms such as pain and reduced joint function. Treatment 
options can be divided into broad categories including non-pharmacologic, 
pharmacologic, complementary and alternative, and surgical (93). Non-pharmacologic 
interventions include patient education, physiotherapy, weight loss, the use of assistive 
devices, and activity modification (44, 102).  Pharmacologic treatments are targeted at 
reducing joint pain and include the use of acetaminophen, non-steroidal anti-
inflammatory drugs (NSAIDs), intra-articular corticosteroid injections, and if necessary 
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opioid analgesics (93, 102). There has been inconsistent evidence for the use of 
complementary and alternative treatments such as glucosamine and/or chondroitin sulfate 
and accupuncture. Thus these treatments may be recommended, but should be 
discontinued if no relief is experienced (102). Lastly, several surgical options are 
available.   Joint replacement is recommended if other treatments fail to provide 
symptomatic relief or maintain joint function (102). Osteotomies (surgical alteration of 
the alignment of the joint) may also be considered in young patients with clear joint 
malalignment that will likely progress to OA (102). 
1.4.6 Natural History  
The natural progression of OA varies from person to person with some individuals 
progressing rapidly and others maintaining a relative stable disease state (30, 31). Several 
risk factors have been identified for the progression of joint dysfunction including 
advanced age and obesity (30, 31).  For the knee joint in particular, malalignment of the 
tibiofemoral joint (i.e. varus or valgus alignment) as well as meniscal injuries have been 
correlated with structural disease progression (30). To complicate matters however, 
studies have demonstrated that symptomatic OA (joint pain and dysfunction) does not 
necessarily correlate with structural OA changes found by imaging (42).  
1.4.7 The Future of OA  
The incidence of OA coupled with the price required to manage the disease has placed a 
serious strain on our health care system and economy. As the average life expectancy 
increases and while risk factors such as obesity remain prevalent among our population, 
the incidence of OA is only expected to increase in the coming years (58). Furthermore, 
studies have recently shown that in addition to morbidity, OA may increase mortality, 
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potentially due to lack physical activity secondary to joint dysfunction and the sequelae 
from long term use of medications, particularly NSAIDs (45).  It is for these reasons that 
a deeper understanding of OA pathology is urgently needed in order to identify effective 
treatment options and ideally find ways to halt and even reverse disease progression. 
1.5 Molecular Mechanisms of Cartilage Degradation 
Articular cartilage degeneration is the hallmark of osteoarthritis (OA). Unlike the classic 
inflammatory disease rheumatoid arthritis (RA), which involves systemic inflammation 
and symmetric joint damage, the cartilage loss seen in OA is usually asymmetric. 
Cartilage degeneration can be caused by an increase in catabolic factors, by a decrease in 
anabolic factors, or by a combination of both. Many signaling molecules play a role in 
cartilage metabolism including cytokines, growth factors, intracellular mediators, 
transcription factors, and enzymes (78). Here we will highlight some of the best-studied 
molecules in OA. 
1.5.1 Catabolic Factors 
The inflammatory mediators TNFα and IL-1β are two predominant catabolic cytokines 
involved in the initiation and progression of cartilage degeneration (33, 50). While 
inflammation definitely plays a role, OA is not considered to be a classical inflammatory 
disease like RA as it lacks systemic inflammatory markers and the presence of 
neutrophils in the synovial fluid (33).  Synovitis (inflammation of the synovium) is 
present in osteoarthritis however, as is cartilage inflammation at the molecular level (50, 
69). TNFα, IL-1β and their specific receptors are upregulated in OA chondrocytes (43). 
In osteoarthritis, elevated levels of these cytokines have been observed in a number of 
joint tissues including the synovial membrane and fluid, subchondral bone, and cartilage 
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(50). TNFα and IL-1β have anti-anabolic and catabolic effects as they have been shown 
to reduce type II collagen, proteoglycan, and link protein synthesis and increase a number 
of catabolic enzymes (50). They also stimulate the production of prostaglandins, nitric 
oxide (NO) via inducible nitric oxide synthase (iNOS), and pro-inflammatory cytokines 
including IL-6, IL-17, IL-18 (33, 50). 
Matrix metalloproteinases (MMPs) are the main catabolic enzymes involved in the 
degradation of the articular cartilage matrix during the disease state of OA. In healthy 
cartilage, these enzymes are synthesized by chondrocytes at a low rate as part of normal 
cartilage maintenance and turnover (43). These enzymes are secreted from the cell into 
the matrix in a pro-enzyme form, where they are eventually cleaved to their active form 
by other MMPs or plasmin (87). MMP activity is further regulated by tissue inhibitors of 
MMPs (TIMPs) whose expression decreases in OA, thus promoting MMP activity (86). 
MMP13 (collagenase-3) is likely the most important enzyme in OA as it is capable of 
degrading type II collagen fibrils with the greatest efficiency (43, 87). There are however 
twenty-three MMP family members, and several including MMP1 (collagenase-1), 
MMP3 (stromelysin), and MMP8 (collagenase-2) have been implicated in cartilage injury 
and OA (35, 43, 87). 
In addition to MMPs, aggrecanases (enzymes that digest the proteoglycan aggrecan) are 
critical enzymes involved in OA. In particular, two members of the ADAMTS (a 
disintegrin and metalloproteinase with thrombospondin motifs) family, namely 
ADAMTS-4 and ADAMTS-5, are expressed by chondrocytes in osteoarthritis and 
ADAMTS-4 is synthesized in response to TNFα and IL-1β (46, 78). 
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In addition to the cytokines and growth factors mentioned above, a number of other 
signaling molecules have been shown to regulate ECM turnover. A great amount of focus 
has shifted to the catabolic role of nitric oxide (NO) in OA pathology (89, 95). NO and 
iNOS are increased in arthritic chondrocytes, and NO itself has been shown to decrease 
type II collagen and proteoglycan synthesis and increase the expression of catabolic 
enzymes (1). NO can also induce chondrocyte apoptosis and positively regulate the NF-
kB (nuclear factor kappa B) pathway. NF-kB is a transcription factor that mediates the 
expression of other proinflammatory cytokines (78).  
1.5.2 Anabolic Factors 
TGFβ is one of the most important anabolic factors in cartilage. It signals through TGFβ 
receptors and downstream Smad activation to increase type II collagen and proteoglycan 
synthesis and to decrease catabolic enzyme production (43, 78). It also counteracts the 
anti-anabolic and catabolic effects of IL-1β (43, 78). In aging and arthritic chondrocytes 
however, the cell’s ability to respond to TGFβ is diminished, thus blunting its anabolic 
potential (78).  
Bone morphogenetic proteins (BMPs) are also members of the TGFβ superfamily and 
activate downstream Smad signaling (43). Several BMPs are involved in articular 
cartilage homeostasis. BMP-2 is upregulated in arthritic chondrocytes, possibly in an 
attempt to maintain matrix integrity (78). BMP-7 which has been shown to delay OA 
progression in in vivo disease models, on the other hand, is downregulated (78).  
IGF-1 signals through the IGF-1 tyrosine kinase receptor to stimulate matrix secretion, 
oppose matrix degradation, and promote chondrocyte survival (33, 43). Interestingly, 
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IGF-1 gene expression is increased in osteoarthritic chondrocytes, however its ability to 
signal is blunted by the presence of inhibitory IGF binding proteins (33, 78). Lastly, 
fibroblast growth factors (FGFs) have a more complicated role in the regulation of 
articular cartilage metabolism. Studies have shown that FGF-2 (also known as basic 
FGF) is released from the cartilage matrix under mechanical stress and appears to have a 
mitogenic effect on chondrocytes (33, 78). This mitogenic effect might be more 
pathologic than anabolic as increased proliferation of chondrocytes is often associated 
with a loss of chondrocyte phenotype (78). FGF-18 in contrast, has a more 
straightforward role stimulating matrix synthesis in articular chondrocytes (78). 
1.6 Signaling Pathways in Osteoarthritis 
1.6.1 Transforming growth factor alpha 
Our laboratory recently identified transforming growth factor alpha (TGFα) as a novel 
growth factor involved in OA from microarray studies performed on degenerating 
cartilage in surgical rodent model of the disease (7). TGFα was first discovered in 
conditioned media from murine sarcoma virus-transformed fibroblastic cells (26). It was 
discovered at the same time as TGFβ and thus the two molecules have similar 
nomenclature despite being structurally unrelated (18, 26, 82). Due to the nature of their 
discovery, TGFα and TGFβ were originally called sarcoma growth factors, but were later 
more appropriately renamed transforming growth factors (82). TGFα itself is a member 
of the epidermal growth factor (EGF) family and is known to play key roles in normal 
growth and development. In particular, TGFα is known to be involved in cell 
proliferation, migration, and differentiation (67). A variety of embryonic and adult tissues 
express TGFα including the brain, skin, gastric mucosa, colon, liver and kidney (62). 
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Furthermore, various tumors and immune cells such as eosinophils, monocytes, 
macrophages, and neutrophils express TGFα (20, 67, 71, 99).  
To better understand the role of TGFα in vivo, several mutant mouse models have been 
studied. Transgenic mice overexpressing Tgfa under control of metallothionein promoter 
developed epithelial hyperplasia, pancreatic metaplasia, hepatocarincoma as well as 
mammary adenocarcinoma (48, 88). Tgfa null mice were also studied and main 
phenotypic changes reported include wavy fur due to unorganized hair follicle 
arrangement, curly whiskers, precocious eye-opening, and corneal inflammation (73).  
Surprisingly, newborn mice appeared to undergo normal post-natal development despite 
altered TGFα expression (48, 73, 88).  
Derived from its 160 amino acid transmembrane precursor (pro-TGFα), the 50 amino 
acid length TGFα must be proteolytically cleaved to its mature, soluble form (28, 68). 
Both the membrane bound and soluble forms contain the characteristic EGF-like domain 
that can bind to the EGF receptor (EGFR) and thereby signal in a juxtacrine or 
paracrine/autocrine fashion, respectively (25, 62, 67).  
1.6.2 Epidermal Growth Factor Receptor Family and Ligands 
The epidermal growth factor receptor is a receptor tyrosine kinase (RTK). As an RTK, 
EGFR binding results in receptor dimerization and activation of the cytoplasmic kinase 
domains (67, 90). Once activated, EGFR can then stimulate a variety of downstream 
signaling pathways including the ras/raf/mitogen activated kinase (MAPK), 
phosphatidylinositol 3-kinase (PI3K)/Akt, phospholipase C (PLC), and Rho GTPase 
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pathways (38, 67, 90). The physiological consequences of EGFR activation are highly 
ligand-and cell type-specific (38, 67, 94). 
1.6.3 EGFR Signaling and Osteoarthritis 
Growing evidence supports the involvement of EGFR signaling in arthritic diseases. Both 
RA and OA patients express a variety of cytokines and growth factors in their synovial 
membranes including IL-1β, TNF-α, and EGF (29).  RA patients express higher levels of 
these cytokines, highlighting quantitative differences in these joint diseases (29). 
Additional studies have detected TGFα in the synovial fluid and synovial membranes of 
arthritic patients, and again these levels were higher in those with RA compared to OA 
(41, 63). Furthermore, TGFα has been detected in control synovium and synovial fluid, 
suggesting a normal physiological role (41). 
The most convincing evidence for the involvement of EGFR signaling in OA 
pathogenesis comes from recent studies involving mutations in mitogen-inducible gene 6 
(MIG6) (105). MIG6 (also known as RALT or Gene 33) is a cytoplasmic protein that 
negatively regulates EGFR signaling through several mechanisms, including the 
inhibition of receptor kinase domains of ERBB1/EGFR and ERBB2 and receptor 
internalization and degradation (32, 37, 101, 103). Homozygous null mutants of the Mig6 
allele were found to develop early degenerative disease in multiple joints including the 
knee, ankle, and temporomandibular joints (49, 105). The Mig6 null joints had classical 
arthritic features such as loss of proteoglycan content, degradation of articular cartilage, 
formation of subchondral cysts, synovial hyperplasia, osteophyte formation, and 
abnormal calcification (49, 105). These studies suggest that increased EGFR signaling is 
sufficient to trigger spontaneous disease progression in vivo.  
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In vitro studies have tried to explain the consequences of EGFR signaling in articular 
cartilage itself. When treated with exogenous EGF, primary rat articular chondrocytes 
show a loss of chondrocyte phenotype through altered chondrocyte morphology as well 
as decreased aggrecan and type II collagen gene expression (56).   
Our own in vitro studies have shown similar effects with TGFα treatment (8). In primary 
articular chondrocyte cultures, TGFα decreased expression of the anabolic genes 
aggrecan (Agc1) and type II collagen (Col2) while it increased gene expression of the 
catabolic factors MMP13 (Mmp13) and TNFα (Tnfa) (7). In addition, TGFα altered 
chondrocyte morphology and induced stress fiber formation (7). Furthermore, articular 
cartilage organ cultures treated with TGFα expressed more MMP13 than controls and 
also displayed other OA-like characteristics such as chondrocyte clustering (8). These 
data indicate that TGFα treatment encourages OA-like phenotypic changes in 
chondrocytes. Our collaborators also found that a subset of human OA patients expressed 
higher than normal TGFα mRNA levels, thus establishing an important correlation 
between our animal model and the human disease state (7).  
After identifying the pathologic effects of TGFα in cartilage, the next logical step was to 
elucidate its signaling pathways. We used pharmacological inhibitors to block 
downstream EGFR pathways and found that the RhoA/ROCK pathway and the 
MEK/ERK branch of the MAPK pathway mediate many TGFα effects (9). Specifically, 
RhoA/ROCK inhibition blocked TGFα-induced morphologic changes to chondrocytes, 
MEK/ERK inhibition blocked the down regulation of anabolic genes, and inhibition of 
both pathways decreased type II collagen cleavage by MMPs (9). 
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1.6.4 Endothelin Receptor and Osteoarthritis 
EGFR signaling is known to overlap and interact with many other signaling systems, 
including G-protein coupled receptors (GPCRs) (38). Recently, much effort has gone into 
studying the interactions between EGFR and the GPCR endothelin receptor A (ET(A)R) 
in cancer cells (10, 66). In articular chondrocytes specifically, it has been observed that 
EGF induces ET(A)R expression as well as that of its ligand, endothelin-1 (ET-1) (76, 
77).  Our interest in interactions between these two signaling systems emerged firstly 
from the fact that like TGFα, ET(A)R gene expression was upregulated in our rodent 
model of OA (7), and secondly from the body of research implicating both systems in OA 
disease progression.  
ET(A)R and its twenty-one amino acid peptide ligand endothelin-1 (ET-1) are well 
known for their vasoconstrictive effects on vascular smooth muscle cells as well as their 
mitogenic effects in cancer cells (66, 79). ET(A)R is a GPCR coupled to the pertussis 
toxin-insensitive G-protein, Gq (66). Binding of ET-1 activates Gq which in turn 
stimulates several downstream pathways including the ras/raf/MAPK, PI3K/Akt, and 
PLC pathways (10, 66). ET-1 is expressed in many cell types and contributes to normal 
cellular processes such as vasomotor tone, proliferation, and development (66). 
There is a great deal of evidence to suggest that both ET(A)R and its ligand play 
important roles in chondrocyte physiology and pathology. Articular chondrocytes were 
first shown to produce and release significant quantities of endothelin in 1997 (53). 
Further studies using rodent articular chondrocytes showed that ET-1 production and 
ET(A)R density increased with age (52, 77). This trend is significant because age is the 
number one risk factor associated with OA (17). Prolonged exposure to ET-1 has also 
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been shown to inhibit proteoglycan and collagen synthesis in rat articular chondrocytes 
(54). These data are complemented by reports that indicate that ET-1 increases 
expression of the matrix metalloproteinases MMP1 and MMP13 in human osteoarthritic 
chondrocytes (72, 84).  Human osteoarthritic chondrocytes also respond to ET-1 with 
increased expression of inducible nitric oxide synthase (iNOS, one enzyme responsible 
for NO production), as well as elevated NO production (72). Overall, endothelin 
signaling appears to discourage matrix synthesis and promote degeneration in articular 
cartilage.  
1.7 Overall Objectives and Hypotheses: 
While OA affects the entire joint, the hallmark of this disease is the degeneration of 
articular cartilage. My colleagues have previously identified transforming growth factor 
alpha (TGFα) as a novel growth factor involved in cartilage degeneration. In vitro 
experiments showed that TGFα had profound effects on the chondrocyte phenotype, 
reducing anabolic factor expression and increasing catabolic factor expression. Based on 
these data, the overarching hypothesis for my thesis is that TGFα promotes OA. 
1.7.1 Objective #1  
To determine the relationship between TGFα and endothelin receptor A (ET(A)R) 
signaling in articular cartilage. 
1.7.1.1 Rationale #1 
ET(A)R signaling and TGFα appear to have similar effects on articular chondrocytes. 
Since both TGFα and ET(A)R are upregulated in the surgical rodent model of OA, the 
potential link between TGFα and ET(A)R signaling deserves further investigation. 
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1.7.1.2 Hypothesis #1 
TGFα will induce ET(A)R expression, and inhibition of ET(A)R will block TGFα–
induced effects in articular cartilage. 
1.7.2 Objective #2 
To characterize the role of TGFα in skeletal development. 
1.7.2.1 Rationale #2 
TGFα and its receptor appear to be important mediators of bone development and 
physiology. However, the role of TGFα in endochondral ossification and growth plate 
physiology has not yet been defined. I intend to study the role of TGFα in endochondral 
ossification and characterize the growth plate phenotype of Tgfa null mice. Furthermore, 
since developmental events appear to be recapitulated in OA, this study may provide 
further insight into the role of TGFα in the disease state. 
1.7.2.2 Hypothesis #2 
Tgfa null mice will experience delayed endochondral ossification.  
Objective #3 
To determine the role of TGFα in osteoarthritis progression in vivo. 
1.7.2.3 Rationale #3 
My lab has studied the effects of exogenous TGFα using articular cartilage cell culture 
and organ culture models. To determine whether these findings are relevant in the in vivo 
disease state, I will evaluate the role of TGFα in both a surgical and spontaneous mouse 
model of OA.  
1.7.2.4 Hypothesis #3 
Tgfa null mice will experience delayed OA progression compared to control littermates in 
both a surgical and an aging model of disease. 
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Chapter 2  
2 Transforming growth factor alpha induces endothelin receptor A in 
osteoarthritis  
This chapter has been reproduced from: 
Usmani SE, Appleton CT, and Beier F. Transforming growth factor-alpha induces 
endothelin receptor A expression in osteoarthritis. J Orthop Res 30: 1391-1397, 2012. 
2.1 Abstract 
Previously, our lab identified transforming growth factor-alpha (TGFα) as a novel factor 
involved in osteoarthritis (OA) in a surgical model of the disease. In the same study, we 
also observed increased transcript levels for endothelin receptor A (ET(A)R), a known 
contributor to cartilage pathology. To investigate the connection between TGFα and 
endothelin signaling in OA, primary articular chondrocytes and osteochondral explants 
were isolated from Sprague Dawley rats and treated with vehicle or TGFα. Expression of 
ET(A)R protein and its encoding gene Ednra was assessed. Chondrocytes and cartilage 
explants were also treated with the endothelin receptor A/B antagonist Bosentan, in order 
to determine whether TGFα effects could be blocked. TGFα induced expression of 
ET(A)R protein and its encoding gene Ednra. In primary chondrocyte cultures, Bosentan 
did not block TGFα responses of the anabolic genes Sox9, Agc1, and Col2a1, but reduced 
the induction of Mmp13 and Ednra transcripts by TGFα. In osteochondral explants, the 
inhibitor partially blocked TGFα reduction of type II collagen, as well as induction of 
MMP13 and type II collagen neoepitopes. TGFα induces ET(A)R expression in articular 
chondrocytes and receptor antagonism appears to block some TGFα -induced catabolic 
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effects in a three-dimensional organ culture system. Thus, TGFα may be a therapeutic 
target upstream of ET(A)R in OA. 
2.2 Introduction 
Osteoarthritis (OA) is the most prevalent disabling condition in western society and 
places a serious strain on our health care system (2).  Clinical symptoms such as joint 
pain and decreased joint function can severely affect day to day life for patients, however 
no cure exists and current treatments only address symptoms without affecting the 
underlying causes (10). As a result, there is a significant need for further investigation 
and understanding of OA pathology.  
While OA is a multivariable disease affecting the entire joint, one defining feature is the 
degeneration of articular cartilage (2). To better understand underlying pathological 
mechanisms, our lab has recently established a genome-wide profile of differentially 
expressed genes in degrading cartilage in a surgical rodent model of OA (5).  
Interestingly, transforming growth factor alpha (TGFα) transcript levels were upregulated 
in degenerating cartilage when compared to controls (5).  Thus TGFα was identified as a 
novel candidate growth factor involved in cartilage degradation.  Further exploration 
revealed that TGFα treatment had profound effects on the chondrocyte phenotype.  For 
example, treatment of monolayer chondrocyte cell cultures with TGFα resulted in 
suppressed expression of anabolic genes including aggrecan and type II collagen while 
matrix metalloproteinase 13 (MMP13) gene expression increased (6). TGFα treatment 
also altered chondrocyte morphology and induced stress fibre formation in monolayer 
cultures (6). Articular cartilage organ culture studies revealed that cartilage treated with 
TGFα expressed more MMP13 than controls and also displayed other OA-like 
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characteristics such as cell clusters (6).  A subset of human OA patients was also found to 
have higher than normal TGFα mRNA levels, thus establishing an important correlation 
between our rodent model and the human disease state (6).  
TGFα is a member of the epidermal growth factor (EGF) family and contains the 
characteristic EGF-like domain which binds to the EGF receptor (16).  While EGF itself 
was down-regulated in our experimental OA model, EGF receptor phosphorylation was 
increased, indicating receptor activation (6). Furthermore, a recent study showed that 
genetically modified mice with enhanced EGFR signaling spontaneously develop OA 
(32). EGFR signaling is also known to overlap and interact many other signaling systems, 
including the G-protein coupled receptor (GPCR) endothelin receptor A (ET(A)R) (11). 
In articular chondrocytes specifically, it has been observed that EGF induces expression 
of ET(A)R as well as of its ligand, endothelin-1 (ET-1) (19, 20).  Our interest in 
interactions between these two signaling systems emerged firstly from the fact that, like 
TGFα, ET(A)R gene expression was upregulated in our animal model of OA (5) and 
secondly from the body of research implicating both systems in OA disease progression.  
Previous studies have indicated that ET(A)R and its ligand play important roles in 
chondrocyte physiology and pathology. Studies using rodent articular chondrocytes 
showed that ET-1 production and ET(A)R density increased with age (14, 20). This trend 
is significant as age is the number one risk factor associated with OA (10). Prolonged 
exposure to ET-1 has also been shown to inhibit proteoglycan and collagen synthesis in 
rat articular chondrocytes (15). These data are complemented by reports which indicate 
that ET-1 increases expression of the matrix metalloproteinases MMP1 and MMP13 in 
human osteoarthritic chondrocytes (17, 23). Human osteoarthritic chondrocytes also 
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respond to ET-1 with increased expression of inducible nitric oxide synthase (iNOS), as 
well as elevated nitric oxide (NO) production (17). Elevated levels of iNOS are also 
characteristic in OA cartilage and studies have shown that inhibitors of iNOS can reduce 
the progression of experimental OA (3, 22, 27). Recently, Kaufman et al., elegantly 
demonstrated that antagonism of ET(A)R prevents articular cartilage degradation in a 
surgical rat model of OA (13). In this study, we hypothesized that TGFα signals upstream 
of ET(A)R and that inhibiting ET(A)R might block some of TGFα’s OA-like changes in 
articular cartilage.  
2.3 Materials and Methods 
2.3.1 Surgical Model of Osteoarthritis  
Tissues from our original surgical OA model were analyzed in this study. Weight 
controlled adult male Sprague Dawley rats underwent anterior cruciate ligament 
transection (ACL-T) and partial medial meniscectomy (PM) of the right knee joint or 
sham surgery as described (4, 12). All animals were exercised on a rotating cylinder for 
30 minutes three times a week in order to allow full flexion and extension of their knee 
joints (4).  
2.3.2 Histology and Immunohistochemistry 
Organ culture explants were fixed overnight in 4% paraformaldehyde and then 
decalcified in an EDTA solution (0.4M EDTA, 0.3N NaOH, 1.5% glycerol and pH 7.3). 
Decalcification was determined by a physical end-point test. Tissues were processed, 
embedded in paraffin wax, and sectioned (6 µm thick) by the Molecular Pathology 
Laboratory at Robarts Research Institute (London, ON, Canada). Immunohistochemistry 
(IHC) was performed by first dewaxing sections in xylene and then rehydrating through a 
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series of graded ethanols ending in water. Antigen retrieval was performed in sodium 
citrate pH 6.0 for cellular proteins or Proteinase K for matrix-specific proteins. Tissues 
were then blocked in 5% serum and incubated with primary antibody overnight at 4oC. 
Incubation with horseradish peroxidise-conjugated secondary antibody was followed by 
colorimetric detection with the substrate diaminodbenzidine (DAB). Primary antibodies 
used include anti-ET(A)R, -ET(B)R and -iNOS (Abcam, Cambridge, MA, USA), anti-
type II collagen (R&D Systems, Minneapolis, MN, USA), anti-MMP13 (Cedarlane, 
Hornby, ON, Canada) and anti-type II collagen neoepitope (7, 9). 
2.3.3 Cell Culture and Organ Culture Studies  
All cell and organ culture reagents were purchased from Invitrogen (Burlington, Ont., 
Canada) and Sigma (Oakville, Ont., Canada) while sterile plates were purchased from 
BD Falcon (Mississauga, ON, Canada).  All cells and explants were maintained in a 37oC 
humidified incubator at 5% CO2 and medium was changed daily. 
2.3.4 Primary Articular Chondrocyte Cell Culture 
Primary articular chondrocytes were isolated from the distal femoral condyles of neonatal 
Sprague Dawley rats as previously described and plated at a density of 5.0 x 104 cells/cm2 
(24). A 10% fetal bovine serum culture medium was prepared from a 2:3 ratio of 
DMEM:F12 supplemented with 50µg/ml ascorbic acid, 0.25% L-glutamine and 0.25% 
penicillin/streptomycin. Chondrocytes were serum starved for 24 hours prior to treatment 
and serum free medium was used throughout the remainder of the time course. 
Chondrocyte culture medium was supplemented with TGFα (final concentration 10 
ng/ml) or an equal volume of vehicle (0.1% bovine serum albumin in PBS) for up to 72 
hours. Culture medium was changed daily. For our endothelin inhibitor studies, cells 
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were treated with vehicle, TGFα (10 ng/ml), the endothelin receptor inhibitor Bosentan 
(10 µM; provided by Actelion Pharmaceuticals Ltd , Allschwil, Switzerland) or a 
combination of both for 48 hours. Bosentan is a dual endothelin receptor A/B antagonist 
which is clinically used for the treatment of pulmonary arterial hypertension (18). 
2.3.5 E15.5 Tibia Organ Culture 
Time-mated CD1 mice were purchased from Charles River Laboratory (St. Constant, 
Quebec, Canada) and embryonic E15.5 tibia were dissected as previously described (1, 
26).  Tibiae were cultured in media containing α-MEM supplemented with ascorbic acid, 
beta-glycerophosphate, bovine serum albumin, PENSTREP®, and L-glutamine. All 
tissues were maintained in a 37oC humidified incubator at 5% CO2 and treated with a 
range of concentrations of recombinant human TGFα  (0 to 1000 ng/ml) for six days. 
Culture medium was changed every other day.  
2.3.6 RNA Isolation and Real-Time PCR 
 RNA was isolated from rat primary chondrocytes using the Qiagen RNeasy Mini Kit and 
the manufacturer’s animal cell protocol (Qiagen, Mississauga, ON, Canada). Mouse 
cartilage was dissected from the ends of tibia organ cultures with the aid of a Zeiss Stemi 
DV4 Stereo microscope as previously described (28), samples were placed in QIAzol 
solution (Qiagen, Mississauga, ON, Canada), and RNA was isolated following the 
manufacturer’s protocol. Real-time PCR was performed for the genes Ednra (endothelin 
receptor A), Il1b (interleukin-1 beta), Cxcr4 (chemokine (C-X-C motif) receptor 4), Tgfa 
(transforming growth factor alpha), Agc1 (aggrecan), Col2a1 (type II collagen), Sox9 
(Sox9), and Mmp13 (matrix metalloproteinase 13). Analysis was performed using the 
Applied Biosystems 7900HT Real-Time PCR system, the TaqMan® One-step Mastermix 
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Kit, and commercially available probes (Applied Biosystems, Foster City, CA, USA).  
All samples were normalized to the housekeeping gene Gapdh and day zero or vehicle-
treated controls using the delta-delta cycle threshold (∆∆CT) method. 
2.3.7 Articular Cartilage Organ Culture 
Osteochondral explants were isolated from the distal femoral condyles and proximal 
tibial plateaus of 4-5 month old adult male Sprague Dawley rats. Explants were then 
placed in 12-well tissue culture plates and submerged in a 2% bovine serum albumin 
culture medium made from alpha-minimal essential medium supplemented with 50µg/ml 
ascorbic acid, 0.25% L-glutamine and 0.25% penicillin/streptomycin for 24 hours prior to 
treatment. The same treatment groups described for primary chondrocyte experiments 
were repeated for organ culture studies. Explants were treated daily for up to 5 days 
before tissues were prepared for histology.  
2.3.8 Rhodamine Phalloidin Staining 
Primary chondrocyte cell cultures were isolated as described above and plated on micro 
cover glasses (VWR, Mississauga, ON, Canada) in 24-well plates at a density of 1.0 x 
104 cells/cm2. Cells were treated with one of four treatments: vehicle, TGFα (10 ng/ml), 
Bosentan (10 µM), or both for 48 hours. Cells were then fixed, permeabilized, and 
stained with rhodamine phalloidin (Cytoskeleton Inc., Denver, CO, USA) to visualize F-
actin and overall cell morphology.  
2.3.9 Statistics 
All statistical analysis was performed using GraphPad Prism software Version 4.0. Real-
time data was analysed using either a one-way analysis of variance (ANOVA) with a 
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Tukey’s post-test or a two-way ANOVA with a Bonferroni’s post-test. All graphs show 
mean values + standard error of the mean (SEM). A minimum of three independent 
groups was used in all experiments.  
2.4 Results 
2.4.1 ET(A)R expression increases in a surgical model of osteoarthritis 
Our previous studies have shown that ET(A)R gene expression is upregulated in OA-
operated animals compared to controls, as demonstrated by microarrays and validated by 
real-time PCR (5). We next wanted to examine ET(A)R protein expression in histological 
samples from OA- and sham-operated animals.  Immunohistochemical analysis revealed 
more ET(A)R signal throughout articular surfaces in OA animals compared to controls 
(Figure 2.1).  
2.4.2 TGFα treatment induces ET(A)R gene expression 
To examine whether TGFα can induce Ednra expression, primary rat chondrocytes in 
monolayer culture were treated with vehicle or TGFα (10 ng/ml) for 1 – 3 days, followed 
by isolation of RNA and real-time PCR analyses. Ednra mRNA expression increased 
after 2 and 3 days of TGFα treatment (Figure 2.2A).  Day 2 showed about a 9-fold 
increase while day 3 showed about a 6-fold increase (Figure 2.2A). In contrast, transcript 
levels of several other genes known to be involved in OA or identified in our microarray, 
including Tgfa itself, Il1b, and Cxcr4, did not change significantly after treatment (Figure 
2.2B-D). We next wanted to determine whether TGFα-induction of Ednra was species 
specific. We therefore employed the mouse E15.5 tibia organ culture system. RNA 
isolated from the cartilage ends of TGFα-treated tibiae also showed an induction of  
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Figure 2.1 Endothelin receptor A (ET(A)R) protein expression is upregulated in 
degenerating cartilage from an experimental rodent model of osteoarthritis (OA). 
Histological sections were prepared from knee joint articular cartilage of both sham and 
OA operated rats 4 weeks post-surgery. Immunohistochemistry was performed with an 
anti-ET(A)R primary antibody followed by secondary antibody and visualization with the 
substrate DAB (brown precipitate).  Nuclei were counterstained with hematoxylin (blue). 
Representative images show more ET(A)R staining in OA cartilage compared to sham 
cartilage. This experiment was performed on three separate trials with similar results and 
one representative trial is shown.  
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Figure 2.1 Endothelin receptor A (ET(A)R) protein expression is upregulated in 
degenerating cartilage from an experimental rodent model of osteoarthritis (OA). 
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Figure 2.2 TGFα treatment increases expression of the endothelin receptor A gene 
(Ednra). Neonatal rat primary chondrocytes were treated with or without TGFα (10 
ng/ml) for up to 3 days (A-D) while E15.5 CD1 mouse tibiae were treated with a range of 
TGFα concentrations (0-1000 ng/ml) for 6 days (E). Real-time PCR was used to 
determine gene expression relative to Gapdh and day 0 controls.  Relative expression 
means +SEM are shown. A) Ednra mRNA expression increased in rat primary cultures 
after days 2 and 3 of treatment while expression of the genes Il1b, Cxcr4 and Tgfa did not 
change significantly after treatment (B-D). Treated mouse tibiae also showed increased 
levels of Ednra transcripts (n=3-4, *P<0.05). 
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Figure 2.2 TGFα treatment increases expression of the endothelin receptor A gene 
(Ednra). 
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Ednra transcripts, although a higher dose of TGFα was required to reach significance 
(Figure 2.2E).  
2.4.3 TGFα treatment induces ET(A)R protein expression 
To study TGFα’s effects on ET(A)R expression in a more physiological three-
dimensional context, articular organ culture explants were isolated from male Sprague 
Dawley rats and treated with or without TGFα. Tissues were immunostained for ET(A)R 
and ET(B)R and representative images from day 1 and day 5 are shown (Figure 2.3A). 
Figure 2.3 reveals an increase in ET(A)R staining in TGFα-treated explants compared to 
controls. No evident change in ET(B)R expression was observed between treatments and 
controls (Figure 2.3A). 
2.4.4 iNOS, and NF-κB expression increase with TGFα treatment  
Endothelin signalling is known to activate iNOS expression (17). Tissue sections from 
articular cartilage organ cultures treated with vehicle or TGFa were stained with 
antibodies against iNOS and the p65 subunit of NF-κB (a transcription factor regulating 
iNOS expression (21)). The TGFα-treated tissues appear to have more positively stained 
cells for iNOS than controls after 5 days of treatment (Figure 2.3B). In particular, 
staining extended deeper into the cartilage in TGFα-treated samples. We saw a similar 
trend for NF-κB staining (Figure 2.3B). 
2.4.5 Bosentan treatment does not block TGFα-induced gene changes 
To address whether inhibition of endothelin receptors can block effects of TGFα on gene 
expression, primary chondrocytes were treated with vehicle, TGFα, the endothelin 
receptor A/B inhibitor Bosentan or both. Bosentan treatment did not block TGFα- 
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Figure 2.3 Endothelin receptor A (ET(A)R) expression increases in TGFα-treated 
articular cartilage explants. Tibial and femoral articular cartilage explants were isolated 
from Sprague Dawley rats and cultured with or without TGFα (10 ng/ml) for up to 5 
days. Histological sections were then immunostained for ET(A)R, ET(B)R, iNOS and 
NF-kB (brown precipitate) and counterstained with hematoxylin (blue).  A) 
Representative images show that ET(A)R expression increased after 5 days of treatment 
while ET(B)R showed no change with TGFα treatment. B) TGFα-treated tissues show 
more staining for both iNOS and the transcription factor NF-kB. This experiment was 
performed on three separate trials with similar results and one representative trial is 
shown.  
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Figure 2.3 Endothelin receptor A (ET(A)R) expression increases in TGFα-treated 
articular cartilage explants. 
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suppression of Agc1, Col2a1, or Sox9 mRNA levels (Figure 2.4A-C); however, Bosentan 
slightly decreased the induction of Ednra (Figure 2.4D) and Mmp13 (Figure 2.4E).  In the 
absence of TGFα, Bosentan did not induce any significant changes in chondrocyte gene 
expression.  
2.4.6 Bosentan treatment does not block TGFα effects on cell morphology 
TGFα has been shown to alter cell shape and induce stress fiber formation in monolayer 
articular chondrocyte cultures (6), in agreement with loss of a chondrocyte phenotype 
(31). As in our earlier studies, TGFα induced stress fiber formation and a more elongated 
cell shape in primary chondrocytes (Figure 2.5). By itself, Bosentan did not appear to 
have any effects on cell morphology or actin organization (Figure 2.5). Moreover, when 
Bosentan treatment was given in combination with TGFα, no major change was observed 
when compared to TGFα treatment alone (Figure 2.5).  
2.4.7 Bosentan treatment blocks TGFα effects on cartilage ECM turnover  
After finding limited effects of endothein receptor A/B inhibition in our monolayer 
articular chondrocyte model, we decided to perform inhibitor studies in the more 
physiologically relevant organ culture model. Explants were cultured with vehicle, 
TGFα, Bosentan or both. Tissue sections were then immunostained for type II collagen, 
MMP13, and type II collagen neoepitopes that become detectable when type II collagen 
is cleaved by MMP13. TGFα-treated tissues showed a decrease in overall type II collagen 
staining in the extracellular matrix (ECM) (Figure 2.6A) and an increase in MMP13 
staining (Figure 2.6B). Co-treatment with Bosentan appeared to reverse these catabolic 
effects (Figure 2.6A,B). Furthermore, TGFα-treatment appeared to generate more type II  
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Figure 2.4 Bosentan treatment does not block TGFα-effects on gene expression. 
Primary articular chondrocytes were cultured with vehicle, TGFα (10 ng/ml), the 
endothelin receptor A/B inhibitor Bosentan (10 µM), or a combination of both for 48 
hours. RNA was isolated and real-time PCR was performed for the genes Acg1, Col2a1, 
Sox9, Ednra, and Mmp13. For all genes, measurements were relative to Gapdh and 
vehicle-treated controls. Bosentan and had a slight effect of induction of Ednra (D) and 
Mmp13 (E). Bosentan did not have a significant effect on any other genes (A, B, C). 
Relative expression means +SEM are shown. Means with different letters are 
significantly different (n=4, P<0.05).  
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Figure 2.4 Bosentan treatment does not block TGFα-effects on gene expression. 
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Figure 2.5 Bosentan treatment does not alter TGFα effects on actin organization. 
Primary articular chondrocytes were cultured and treated with vehicle, TGFα (10 ng/ml), 
the endothelin receptor inhibitor A/B Bosentan (10 µM), or a combination of both for 48 
hours. Cells were then fixed and stained with rhodamine phalloidin (red) in order to 
visualize F-actin. Nuclei were stained with DAPI (blue). Representative images of each 
treatment are shown (n=3). Bosentan does not block TGFα effects on cell morphology or 
induction of stress fibers.  
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Figure 2.5 Bosentan treatment does not alter TGFα effects on actin organization. 
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Figure 2.6 Bosentan treatment blocks TGFα reduction of type II collagen, induction 
of MMP13, and induction of type II collagen neoepitopes. Articular cartilage explants 
were treated with vehicle, TGFα (10 ng/ml), the endothelin receptor A antagonist 
Bosentan (10 µM), or both for 5 days. Tissues were then immunostained for type II 
collagen (A), MMP13 (B), and type II collagen neoepitopes (C) (brown precipitate). 
TGFα-treated tissues showed a decrease in type II collagen staining, an increase in 
MMP13 staining, and an increase in type II collagen neoepitopes. Co-treatment with 
TGFα and Bosentan appeared to bring expression levels back to control levels. This 
experiment was performed on four separate trials with similar results and one 
representative trial is shown.  
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Figure 2.6 Bosentan treatment blocks TGFα reduction of type II collagen, induction of 
MMP13, and induction of type II collagen neoepitopes. 
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collagen neoepitopes in the ECM when compared to controls, but the combination with 
Bosentan appeared to block neoepitope induction (Figure 2.6C). 
2.5 Discussion 
We have previously identified TGFα as a growth factor capable of inducing OA-like 
phenotypic changes in articular chondrocytes. In this study, we demonstrate that TGFα 
induces ET(A)R expression in articular chondrocytes at both the gene and protein level. 
Furthermore, we demonstrate that TGFα-induction of the receptor occurs in both rat and 
mouse models as well as in varying ages of tissue (embryonic, newborn, and four-five 
month-old). This is consistent with previous findings, in which EGF was able to induce 
ET(A)R expression in both young and old rats (20). In addition to EGF and TGFα, a 
number of other growth factors and cytokines are known to modulate ET(A)R receptor 
density in chondrocytes (20). Furthermore, the literature suggests that the ET(A)R 
receptor plays a role in both aging and degenerative joint disease (14, 17, 20, 23). Thus, 
TGFα induction of ET(A)R might be one way through which TGFα mediates its 
deleterious effects.  
To test this hypothesis, we used the dual endothelin receptor A/B inhibitor Bosentan in 
combination with TGFα treatment. We found that Bosentan treatment was not sufficient 
to block TGFα-effects on anabolic gene expression in monolayer culture. Bosentan did, 
however, have a minor effect on Mmp13 and Ednra levels. Bosentan was also unable to 
reverse TGFα-induced changes to the chondrocyte actin cytoskeleton and cell shape. 
This leads us to believe that other downstream pathways might be responsible for 
anabolic gene expression changes and cytoskeletal rearrangement in TGFα-treated 
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chondrocytes. Previous studies done in our laboratory show that TGFα activates many 
intracellular signalling pathways (7).  For example, RhoA/ROCK mediates TGFα-
induced morphologic changes in chondrocytes, in agreement with our previous studies 
demonstrating important roles of this pathway in chondrogenesis (29, 30). The 
MEK/ERK pathway mediates the down regulation of anabolic gene expression by TGFα 
(7), again line with the known roles of this pathway in chondrocytes (reviewed in (8, 
25)). Both Rho/ROCK and MEK/ERK pathways also regulate type II collagen cleavage 
and aggrecan breakdown in articular cartilage (7).  
Bosentan had a stronger effect in the three-dimensional organ culture system where 
endothelin receptor A/B inhibition was able to suppress TGFα induction of the catabolic 
factor MMP13 and subsequent type II collagen break down. There are some possible 
explanations for the differences observed in our two experimental systems. Firstly, age 
may play a role: primary cells used in our studies were isolated from neonatal rats while 
organ culture explants were isolated from adult rats. The baseline density of ET(A)R 
receptors is known to be dependent on the age of articular chondrocytes and more ET-1 is 
known to be produced in older chondrocytes (14, 20). In addition, endothelin receptor 
signaling might be more important in the authentic three-dimensional context of cartilage 
than in monolayer culture. Recently, Kaufman et al. showed that ET(A)R inhibition 
prevented OA progression in a surgical model of the disease (13), in agreement with our 
data shown here. 
In our studies, we observed no effect on any parameters with Bosentan treatment alone. 
While articular chondrocytes produce ET-1, it is possible that its levels are not high 
enough in the in vitro environment to sufficiently stimulate ET(A)R receptors. ET-1 
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mRNA levels however, did not change in the TGFα treatment groups (data not shown), 
suggesting that it is the receptor density itself more so than the concentration of ligand 
that is responsible for enhanced signaling.  
In summary, our data show that ET(A)R expression in articular cartilage is increased in 
response to both surgical induction of OA and TGFα treatment. We also demonstrate that 
this pathway is only partially responsible for TGFα-induction of an OA-like phenotype, 
but that ET(A)R inhibition suppresses catabolic activities in articular cartilage. Further 
studies should be done to examine the potential benefit of upstream targets such at the 
EGF receptor itself as well as combinations of downstream targets in OA therapy. 
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Chapter 3  
3 Transforming growth factor alpha controls the transition from hypertrophic 
cartilage to bone during endochondral bone growth 
This chapter has been reproduced from: 
Usmani SE, Pest MA, Kim G, Ohora SN, Qin L, and Beier F. Transforming growth 
factor alpha controls the transition from hypertrophic cartilage to bone during 
endochondral bone growth. Bone 51: 131-141, 2012. 
3.1 Abstract 
We have recently identified transforming growth factor alpha (TGFα) as a novel growth 
factor involved in the joint disease osteoarthritis. The role of TGFα in normal cartilage 
and bone physiology however, has not been well defined. The objective of this study was 
to determine the role of TGFα in bone development through investigation of the Tgfa 
knockout mouse. The gross skeletons as well as the cartilage growth plates of Tgfa 
knockout mice and their control littermates were examined during several developmental 
stages ranging from newborn to ten-weeks-old. Knockout mice experienced skeletal 
growth retardation and expansion of the hypertrophic zone of the growth plate. These 
phenotypes were transient and spontaneously resolved by ten weeks of age. Tgfa 
knockout growth plates also had fewer osteoclasts along the cartilage/bone interface. 
Furthermore, knockout mice expressed less RUNX2, RANKL, and MMP13 mRNA in 
their cartilage growth plates than controls. In conclusion, Tgfa knockout mice experience 
a delay in bone development, specifically the conversion of hypertrophic cartilage to true 
bone. The persistence of the hypertrophic zone of the growth plate appears to be 
mediated by a decrease in MMP13 and RANKL expression in hypertrophic chondrocytes 
and a resulting reduction in osteoclast recruitment. Overall, TGFα appears to be an 
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important growth factor regulating the conversion of cartilage to bone during the process 
of endochondral ossification.  
3.2 Introduction 
Our lab has recently identified transforming growth factor alpha (TGFα) as a novel factor 
involved in the degeneration of articular cartilage during osteoarthritis (3-5).  
Specifically, TGFα treatment modifies articular chondrocyte gene expression by 
decreasing levels of anabolic genes such as type II collagen (Col2a1) and aggrecan 
(Agc1) and increasing levels of catabolic genes such as matrix metalloproteinase 13 
(Mmp13) (4). While much of our efforts have focused on TGFα’s role in joint pathology, 
its role in normal bone and cartilage physiology, in particular during endochondral 
ossification, needs to be understood to fully appreciate its function in disease.   
Endochondral ossification is a highly regulated process that begins when mesenchymal 
stem cells condense and differentiate into chondrocytes, providing an initial cartilage 
template that will eventually be replaced by bone (26, 28). Within the condensations, 
chondrocytes proliferate and secrete a characteristic matrix composed primarily of type II 
collagen and aggrecan (6, 28). Cells at the centre of the condensations stop proliferating, 
undergo hypertrophy, and secrete a matrix rich in type X collagen (28, 31). The 
hypertrophic chondrocytes attract blood vessels, direct the mineralization of their 
surrounding matrix, and ultimately undergo apoptosis (31). Osteoclasts and osteoblasts 
are then recruited in order to resorb hypertrophic cartilage and to replace it with true 
bone, respectively (26, 31). Eventually, secondary ossification centres form near the ends 
of developing bones, and the area between the two ossification centres is known as the 
cartilage growth plate (28). The growth plate consists of distinct layers, namely the 
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resting zone, the proliferating zone, and the hypertrophic zone (31). Proliferation of 
chondrocytes and subsequent cell enlargement during chondrocyte hypertrophy are the 
main drivers of endochondral bone growth (7) . 
Several studies have suggested a potential role of TGFα in early bone development. 
TGFα is a member of the epidermal growth factor (EGF) family and contains the 
characteristic EGF-like domain which allows it to bind to and signal through the EGF 
receptor (EGFR) (29). Both TGFα and EGF negatively regulate chondrogenesis of limb 
bud mesenchymal cells during embryonic development (10, 16, 51).  Other studies have 
examined long bone development in embryonic and neonatal EGFR null mice and found 
delayed endochondral ossification, inhibited osteoclast recruitment, and an expanded 
hypertrophic zone of the growth plate (49). Since EGFR null mice die soon after birth, 
postnatal development could not be assessed. Another group studied the effects of 
reduced EGFR signaling in older animals by creating a conditional knockin mouse 
humanized for Egfr (39). These mice survived up to six months of age, experienced 
growth retardation, as well as accelerated chondrocyte and osteoblast differentiation (39). 
Since both of these models target the EGF receptor itself, the identity of the physiological 
ligand(s) responsible for the aforementioned effects remains unknown. 
TGFα has also been implicated in bone maintenance and turnover. Human recombinant 
TGFα stimulates bone resorption and inhibits bone formation in vitro (17, 18). In these 
studies fetal rat long bones and neonatal mouse calvariae were cultured and resorption 
was assessed by calcium release while bone formation was assessed by collagen synthesis 
and alkaline phosphatase activity (17, 18). These results are similar to those for EGF 
treatment, but TGFα appears to be a more potent agent, inducing the same results with a 
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more rapid time course (17).  Tumor-derived TGFα also causes calcium release in vitro, 
supporting the hypothesis that TGFα may be responsible for the increased bone 
resorption and hypercalcemia seen in some malignancies (18). Additional studies have 
attempted to identify the mechanisms through which TGFα mediates its effects in bone. 
TGFα treatment of human marrow cultures was found to stimulate the formation of 
multinucleated osteoclast-like cells by encouraging the proliferation of precursor cells 
(42). Furthermore, co-cultures of osteoblastic cells and bone marrow macrophages (pre-
osteoclasts) showed that TGFα treatment stimulates osteoclastogenesis by regulating 
osteoblast production of osteoprotegerin (OPG) and monocyte chemoattractant protein 1 
(MCP1, also called CCL2) (53).  
TGFα and its receptor appear to be important mediators of bone development and 
physiology. However, the role of TGFα in endochondral ossification and growth plate 
physiology has not been clearly defined. Tgfa knockout mice were initially characterized 
in 1993 and the main phenotypes reported include wavy fur, disorganized hair follicle 
arrangement, curly whiskers, and corneal inflammation (32). There have been no reports 
of cartilage and/or bone abnormalities.  In this study, we examined the role of TGFα in 
endochondral ossification and characterized the growth plate phenotype of Tgfa null 
mice.  
3.3 Materials and Methods 
3.3.1 Materials 
All cell and organ culture media reagents were purchased from Invitrogen (Burlington, 
ON, Canada) and Sigma (Oakville, ON, Canada) while sterile plates were purchased 
from BD Falcon (Mississauga, ON, Canada). 
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3.3.2 E15.5 tibia organ culture  
Time-mated CD1 mice were purchased from Charles River Laboratory (St. Constant, 
Quebec, Canada). Tibiae were dissected from embryonic 15.5-day-old (E15.5) CD1 mice 
and cultured in media containing α-MEM supplemented with ascorbic acid, beta-
glycerophosphate, bovine serum albumin, PENSTREP®, and L-glutamine as described 
previously (1, 44). Tibiae were maintained in a 37oC humidified incubator at 5% CO2 and 
cultured for six days. Tissues were treated with a range of concentrations of recombinant 
human TGFα  (0 to 1000 ng/ml) every other day. On day one and day six tibiae were 
measured using a Zeiss Stemi DV4 Stereo microscope equipped with an eyepiece ruler. 
Growth was determined by subtracting the length on day 1 from the length on day 6. Four 
independent trials were averaged, and mean growth was analyzed using a one-way 
ANOVA with Tukey’s post-tests. Whole tibiae were stained with alcian blue and alizarin 
red as previously described (44). RNA was also collected from the cartilage growth plates 
of these organ cultures in order to perform real-time PCR (see below).   
3.3.3 Transforming growth factor alpha knockout mice 
Tgfa null mice were purchased from The Jackson Laboratory (Bar Harbor, Maine, USA).  
All animals were bred and cared for in accordance with the University of Western 
Ontario’s Animal Care and Use Guidelines. Heterozygous mice were crossed with each 
other so that litters with all three genotypes (wild type, heterozygous, homozygous null) 
could be obtained. PCR genotyping was performed using DNA from digested ear and/or 
tail clippings. Two separate genotyping programs were used to amplify both the wild type 
Tgfa allele and the neo-cassette found in the mutated alleles. Oligonucleotides 
TGFalphaA (5’-GACTAGCCTGGGCTACACAGTG-3’) TGFalphaC (5’-
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ACATGCTGGCTTCTCTTCCTGC-3’), NeoForward (5’-CTTGGGTGGAGA 
GGCTATTC-3’) and NeoReverse (5’-AGGTGAGATGACAGGAGATC-3’) were 
purchased from Sigma-Aldrich (Oakville, Ont., Canada) and all other genotyping 
reagents were purchased from Applied Biosystems Incorporated (Foster City, CA, USA). 
Animals were sacrificed by various methods depending on age (P0- decapitation, P10- 
intraperitoneal euthanal (pentobarbital sodium) injection, older animals- CO2 chamber).   
3.3.4 Skeletal preparations 
Twenty-one day old (P21) and ten-week-old wild type, heterozygous, and Tgfa null 
littermates were sacrificed, eviscerated and full skeletons were stained with alizarin red 
and alcian blue as previously described (48). Three sets of littermates (each containing 
one wild type, one heterozygous, and one knockout mouse) were analyzed for each age 
group.  
3.3.5  Histology 
Newborn (P0), P21, and ten-week-old littermates were sacrificed. Tibiae only were 
isolated from P0 mice while tibiae and humeri were isolated from P21 and ten-week-old 
mice. Tibiae and humeri were chosen because they represent long bones from the fore 
and hind limbs, and also represent both proximal and distal bones. Tissues were fixed 
overnight in 4% paraformaldehyde (PFA) and decalcified as required in a 5% EDTA 
solution. Decalcification was not required for P0 tissues and was determined by a 
physical endpoint test in older tissues. Tissues were then processed, embedded in paraffin 
wax, and 5 µm thick sections were prepared by the Molecular Pathology Laboratory at 
the Robarts Research Institute (London, ON, Canada).  
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3.3.6 Safranin-O/fast green staining 
Sections were dewaxed in xylene and rehydrated through a series of graded ethanols 
ending in water. Tissues were stained in 0.02% fast green for 25 minutes, dipped in 1% 
glacial acetic acid, then stained in 0.1% safranin-O for 7 minutes. Tissues were 
dehydrated and coverslips were mounted using a xylene-based mounting medium.  
3.3.7 Bone length and growth plate zone measurements 
Prior to decalcification, the lengths of tibiae and humeri were measured using a Zeiss 
Stemi DV4 Stereo microscope with eyepiece. The long bones of three sets of littermates 
were measured for P21 and ten-week-old mice and data were analyzed using one-way 
ANOVAs and Tukey’s post-tests. 
Pictures were taken of the growth plates of P0, P21, and ten–week-old littermates using a 
Retiga EX camera connected to a Leica DMRA2 microscope. Growth plate zones 
(resting, proliferating, hypertrophic) were measured by a blinded observer using 
OpenLab 4.0.4 software. The growth plate zones were distinguished by the unique 
morphology of residing chondrocytes (resting zone - small and round, proliferating zone - 
stacked and disc-like, hypertrophic zone - clearly enlarged), and the blinded observer had 
expertise in the arrangement and organization of the growth plate.  Three sets of 
littermates were used for each age group and measurements were statistically analyzed 
using two-way ANOVAs with Bonferroni post-tests. 
3.3.8 TRAP staining and immunohistochemistry 
In order to assess osteoclast number, tartrate resistant acid phosphatase (TRAP) staining 
was performed on P21 tissues according to the manufacturer’s protocol with some 
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modifications as previously described (43). TRAP staining was quantified in P21 tibiae 
by counting the number of TRAP-positive foci along the cartilage/bone junction. An area 
extending 1000 µm wide and 200 µm long (100 µm above and 100 µm below the 
junction) was outlined. All positive foci within this area were included. Counts from 
three independent trials were recorded and analyzed using one-way ANOVA with 
Tukey’s post-tests. Immunohistochemistry was also carried out as previously described 
(40, 45, 48). Primary antibody incubation occurred overnight at 4oC. Primary antibodies 
included anti-platelet endothelial cell adhesion molecule 1 (PECAM-1) antibody (sc-
1506-R, Santa Cruz, Santa Cruz, CA, USA). Incubation with horseradish peroxidase-
conjugated secondary antibody (sc-2004, Santa Cruz, Santa Cruz, CA, USA) was 
followed by colorimetric detection with the substrate diaminobenzidine (DAB). For all 
staining, three independent trials were used, and representative images are shown. 
3.3.9 RNA isolation and real-time PCR 
Growth plates were dissected from the ends of P0 tibiae and humeri with the aid of a 
Zeiss Stemi DV4 Stereo microscope as previously described (48). To avoid 
contamination, all surrounding connective tissue was removed and growth plates were 
rinsed in sterile Puck’s Solution A. To ensure that the entire growth plate was collected, 
cartilage was removed with a scalpel just above the mineralized zone. Cartilage was 
clearly distinguishable from the grey area of mineralization.  Alternatively, RNA was 
isolated from E15.5 tibia cartilage at the end of culture as described (21, 22). Samples 
were placed in QIAzol solution (Qiagen, Mississauga, ON, Canada), and RNA was 
isolated following the manufacturer’s protocol. RNA was quantified and its quality was 
assessed before real-time PCR was carried out as described (48, 50). Analyses were 
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performed using the Applied Biosystems 7900HT Real-Time PCR system, the TaqMan® 
One-step Mastermix Kit, and commercially available probes (Applied Biosystems, Foster 
City, CA, USA).  All samples were normalized to the housekeeping gene Gapdh and wild 
type controls using the delta-delta cycle threshold (∆∆CT) method. Statistical analysis 
was carried out using paired t-tests.  
3.3.10 Statistical analysis 
All statistical analysis was performed using GraphPad Prism software Version 4.0 and 
graphs show mean values + standard error of the mean (SEM). A minimum of three 
independent groups was used in all experiments.  
3.4 Results 
3.4.1 Human recombinant TGFα  does not affect growth of E15.5 tibiae in 
organ culture 
E15.5 mouse tibia organ cultures were treated with and without exogenous TGFα (0-
1000 ng/ml) for six days. Representative images show control and treated tibiae (Figure 
3.1A). Length measurements at the beginning and end of culture showed no change in 
overall growth over a range of TGFα concentrations (Figure 3.1B). This absence of 
effects suggests that TGFα is not a major regulator of chondrocyte proliferation or 
hypertrophy.  
3.4.2 Tgfa null mice have shorter tibiae than their littermates 
 Full skeletons of male P21 wild type, heterozygous, and knockout littermates were 
stained with alizarin red and alcian blue (Figure 3.2A). No gross skeletal abnormalities 
were observed. However, mutant mice had significantly shorter tibiae than their wild type  
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Figure 3.1 Growth of TGFα-treated tibia organ cultures. Tibiae were isolated from 
E15.5 CD1 mice, grown in culture and treated with a range of TGFα concentrations. 
Whole tibiae were stained with alizarin red and alcian blue at the end of culture (A). 
Average growth over a six-day period was measured and is represented in millimetres 
+SEM (B). There is no change in growth with any of the concentrations used (n=4).  
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Figure 3.1 Growth of TGFα-treated tibia organ cultures. 
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Figure 3.2 Tgfa null mice have shorter tibiae than their littermates. P21 and ten-
week-old mice were sacrificed and skeletons were stained with alizarin red and alcian 
blue (A, D). Mean length of P21 tibiae (B) and humeri (C) as well as ten-week-old tibiae 
(E) and humeri (F) + SEM is shown. P21 knockout mice have significantly shorter tibiae 
and humeri than their littermates, but no differences were seen at ten weeks of age. WT= 
wild type, Het= heterozygous, KO= knockout (n=4/group, *: p<0.05). 
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Figure 3.2 Tgfa null mice have shorter tibiae than their littermates. 
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(8.7% reduction) and heterozygous (7.3% reduction) littermates (Figure 3.2B). Mutant 
humeri were also found to be shorter than wild type and heterozygous littermates by 
about 6.4% (Figure 3.2C).  To determine whether this phenotype was transient or 
persistent, we prepared skeletons and measured bones of ten-week-old male animals 
(Figure 3.2D). There were no significant differences in the length of tibiae or humeri at 
this time point (Figure 3.2E, F). Similar results were seen for female littermates (data not 
shown). With the exception of P21 females, body weight was not significantly different 
between genotypes (data not shown), suggesting that TGFα deficiency specifically 
affects skeletal growth.  
3.4.3 Tgfa null mice have expanded hypertrophic zones  
In order to assess growth plate organization, growth plates from P0, P21, and ten-week-
old mice were stained with safranin-O and fast green. Figure 3.3 shows representative 
images and measurements from these animals. P0 and P21 Tgfa null mice have well 
organized growth plates with clearly expanded hypertrophic zones (Figure 3.3A). 
Measurement of growth plate zone lengths demonstrated that the hypertrophic zone, as 
well as the total growth plate, were significantly longer in Tgfa null mice when compared 
to their littermates, while length and organization of the resting and proliferating zones 
were unchanged (Figure 3.3B, 3.3C). In contrast, ten-week-old mice showed no 
differences in length of individual growth plate zones or the overall length and 
organization of the growth plate (Figure 3.3A, D). Similar findings were also found in 
female mice (data not shown).  
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Figure 3.3. Tgfa null mice have expanded hypertrophic zones. P0 and P21 and ten-
week-old tibia growth plates were stained with safranin-O and fast green (A). Growth 
plate zones (RZ= resting zone, PZ = proliferating zone, HZ= hypertrophic zone) were 
measured for P0 (B), P21 (C), and ten-week-old (D) animals.  Mean lengths +SEM are 
shown. P0 and P21 knockout mice have larger hypertrophic zones (labeled by double 
arrows) and larger growth plates overall than their littermates. No change in growth plate 
zones was observed at ten weeks. WT= wild type, Het= heterozygous, KO= knockout 
(n=4/group, *: p<0.05). 
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Figure 3.3 Tgfa null mice have expanded hypertrophic zones. 
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3.4.4 Tgfa null mice have fewer osteoclasts than their littermates 
Our analysis of growth plate zones did not suggest effects of TGFα deficiency on the 
initiation of hypertrophy, suggesting that the larger hypertrophic zones in Tgfa null mice 
might be due to delayed resorption of cartilage. In order to assess osteoclast number, 
tartrate resistant acid phosphatase (TRAP) staining was performed on P21 tissues.  TRAP 
staining was observed in early trabecular, cortical, and subchondral bone, and differences 
were observed near the growth plate/trabecular interface (Figure 3.4A).  Tgfa null tissues 
have diminished TRAP staining compared to their wild type and heterozygous littermates 
(Figure 3.4A). The number of TRAP-positive foci was quantified along the 
cartilage/bone junction, and Tgfa null mice were found to have significantly fewer 
positive foci than their littermates (Figure 3.4B). Heterozygous mice also had 
significantly fewer TRAP-positive foci compared to wild type mice, indicating that 
TRAP expression may be dose dependent (Figure 3.4B). We also performed TRAP 
staining on P0 and ten day old (P10) tissues. While we found no major differences at P0, 
P10 patterns appeared similar to those of P21 showing less TRAP staining along the 
growth plate/trabecular bone border in mutant animals (Supplementary Figure 3.1).  
3.4.5 RUNX2, MMP13, and RANKL gene expression are decreased in Tgfa 
null mice 
To better understand the mechanisms at work in the mutant growth plate, we isolated 
RNA from cartilage of P0 litters and performed real-time PCR on a number of genes 
known to be involved in cartilage and/or bone development. In particular, we dissected 
the cartilage region giving rise to the secondary ossification center to examine genes 
involved in this process. We found that mRNA levels of a number of genes including 
Sox9, Acan (encoding aggrecan), Col2a1 (type II collagen), Col10a1 (type X collagen),  
93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
94 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Tgfa null mice show reduced TRAP staining compared to their 
littermates. P21 tissues were stained for the osteoclast (OC) marker tartrate resistant acid 
phosphatase (TRAP, dark purple)(A). The number of TRAP-positive foci were then 
quantified along the cartilage/bone interface (B). There are fewer OCs along the cartilage 
growth plate/trabecular bone interface in knockout mice compared to their wild type and 
heterozygous littermates. As well, there are significantly less TRAP-positive foci in the 
heterozygous group compared to the wild type group. WT= wild type, Het= 
heterozygous, KO= knockout (n=3/group, * : p<0.05). 
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Figure 3.4 Tgfa null mice show reduced TRAP staining compared to their littermates. 
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Figure 3.5 Runx2, Mmp13, and Tnfs11 expression are decreased in cartilage of Tgfa 
null mice. RNA was isolated from the growth plates of long bones of P0 mice and the 
expression of genes known to be involved in cartilage and bone physiology was assessed 
by real-time PCR. Many genes showed no change in expression levels between 
genotypes (A, B, C, E, G, I, J, K, L, M) while Runx2, Mmp13, and Tnfs11 mRNA levels 
were all decreased in knockout animals (D, F, H). WT= wild type, KO = knockout 
(n=4/group, *: p<0.05).  
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Figure 3.5 Runx2, Mmp13, and Tnfs11 expression are decreased in cartilage of Tgfa null 
mice. 
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Ihh (Indian hedgehog), Tnfrs11b (encoding osteoprotegerin, OPG), Ptch1 (patched 1), 
Vegfa (vascular endothelial growth factor A), Mmp9 (matrix metalloproteinase 9) and 
Mmp14 (matrix metalloproteinase 14) remained unchanged between genotypes (Figure 
3.5).  However, expression levels of Mmp13 (matrix metalloproteinase 13), Tnfs11 
(encoding receptor activator of nuclear factor kappa-B ligand, RANKL), and Runx2 
(runt-related transcription factor 2) were significantly reduced in mutant animals when 
compared to wild type littermates (Figure 3.5D, 3.5F, 3.5H). 
3.4.6 E15.5 tibiae treated with TGFα  show an increase in expression of late 
hypertrophic markers 
To examine whether TGFα can increase expression of those genes reduced in TGFα-
deficient cartilage, RNA was collected from the growth plates of E15.5 organ cultures 
treated with a range of TGFα concentrations. While no change in overall growth was 
noted (Figure 3.1), real-time PCR analyses reveal changes in the expression of 
hypertrophic markers. Notably, early hypertrophic markers including p57 and ColX were 
decreased with TGFα treatment while late hypertrophic markers including Mmp9, 
Mmp13, and Mmp14 were increased (Figure 3.6B-F). Furthermore, expression of the 
RANKL gene was increased with TGFα treatment (Figure 3.6G). A number of other 
genes (Sox9, Acan, Col2a1, Aft3, Runx2, Vegfa) showed no change in expression with 
TGFα treatment (Supplementary Figure 3.2).  
3.4.7 Tgfa null mice experience delayed secondary ossification 
To analyze whether secondary ossification would be affected in a manner similar to 
primary ossification, we examined the secondary ossification centers of P10 mice. Tgfa 
null mice showed delayed secondary ossification when compared to both wild type and  
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Figure 3.6 Early hypertrophic markers are decreased and late hypertrophic 
markers are increased in TGFα-treated E15.5 tibia organ cultures. Tibiae were 
isolated from E15.5 CD1 mice, grown in culture and treated with a range of TGFα 
concentrations. After 6 days of treatment, RNA was isolated from the cartilage of these 
tibiae (region depicted in A) and real-time PCR was performed (B-G). Data reveal 
decreases in p57 and ColX, as well as increases in Mmp9, Mmp13, Mmp14, and Tnfs11 
transcript levels with treatment (n=3-4/group, *: p<0.05). 
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Figure 3.6 Early hypertrophic markers are decreased and late hypertrophic markers are 
increased in TGFα-treated E15.5 tibia organ cultures. 
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Figure 3.7 Tgfa null mice experience delayed secondary ossification and less 
PECAM-1 staining. P10 long bones were isolated and stained with safranin-O and fast 
green in order to observe secondary ossification centers (SOC). Knockout mice show the 
persistence of hypertrophic cells and an overall delay in secondary ossification compared 
to their littermates. Representative images show the SOCs of proximal humeri in the 
three genotypes. P10 long bones were stained with an anti-platelet endothelial cell 
adhesion molecule (PECAM-1) antibody in order to locate areas of vascularization. 
Knockout mice show less PECAM-1 staining than their littermates in the secondary 
ossification centers. WT= wild type, Het= heterozygous, KO= knockout (n=3). 
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Figure 3.7 Tgfa null mice experience delayed secondary ossification and less PECAM-1 
staining. 
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heterozygous littermates (Figure 3.7). To examine vascular invasion during the formation 
of secondary ossification centers, we performed IHC with an antibody against platelet 
endothelial cell adhesion molecule-1 (PECAM-1), a marker of endothelial cells. We 
found less PECAM-1 staining in the secondary ossification centers of knockout animals 
than in those of their littermates (Figure 3.7).  
We also analyzed PECAM-1 staining at the growth plate/trabecular bone interface in P0, 
P10, and P21 tissues. PECAM-1 expression appeared similar among all genotypes at P0, 
but mutant tissues showed reduced PECAM-1 staining at P10 and P21 (Supplementary 
Figure 3.3).  
3.5 Discussion  
Our data show that Tgfa knockout (KO) mice have a transient growth plate and resulting 
skeletal growth phenotype that appears to resolve by ten weeks of age. Phenotypic 
changes include shorter tibiae and humeri, an enlarged hypertrophic zone and overall 
growth plate length, delayed primary and secondary ossification, and reduced osteoclast 
staining at the cartilage/bone junction. 
The most dramatic aspect of this phenotype is the expanded hypertrophic zone. The 
appearance of the Tgfa null hypertrophic zone is similar to that of the Egfr knockout 
mouse previously described (49). However, Egfr mutants did not survive long after birth, 
and consequently analyses focused on embryonic and newborn mice only (49).  While we 
studied post-natal time points, the resemblance between the two models is clear.  
Moreover, our collaborators recently showed a similar phenotype as described here in 
rats treated with an EGFR inhibitor and in mice with cartilage-specific inactivation of 
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EGFR (52). Since TGFα signals through the EGFR, it is likely that TGFα the major 
ligand responsible for regulating the terminal steps in endochondral ossification, 
specifically the replacement of hypertrophic cartilage by bone. However, the fact that the 
phenotype of Tgfa knockout mice is less severe than that of Egfr knockout mice suggests 
the involvement of additional EGFR ligands in this process.  
TGFα effects in our organ culture experiments (that were performed at an early stage in 
skeletal development when mineralization had barely begun) are limited to markers of 
later stages of hypertrophy. This finding supports the model that TGFα does not directly 
control chondrocyte proliferation or early differentiation, but rather cartilage conversion 
to bone tissue. In contrast to our findings, classical experiments in mesenchymal 
micromass culture have indicated that TGFα is inhibitory to chondrogenesis (16).  It is 
possible that TGFα effects may vary depending on the extent of chondrocyte 
differentiation at the start of the experiment (mesenchymal cells verses growth plate 
chondrocytes) as well as on the system of study (micromass cell culture versus in vivo 
and organ culture studies). Similarly, we recently showed mitogenic effects of TGFα on 
articular chondrocytes (4), while both our current study and results from our collaborators 
(52) suggest that TGFα does not affect growth plate chondrocyte proliferation.  
In our studies, it appears that reduced osteoclast numbers are responsible for the 
persistence of hypertrophic cartilage. Our data show a clear decrease in the amount of 
TRAP staining at the cartilage/bone interface in mutant animals when compared to 
controls. The same localized pattern of staining was observed in rats treated with an 
EGFR inhibitor (52). Furthermore, RANKL gene expression is decreased in cartilage of 
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our mutant animals. RANKL is a key regulator of osteoclastogenesis and is required for 
bone and cartilage resorption (27). Chondrocyte-produced RANKL is able to induce 
osteoclast formation (46), and RANKL-deficient mice show an expanded hypertrophic 
zone similar to the one in our mice (25).  A reduction in RANKL expression could 
explain why we see fewer osteoclasts in Tgfa null tissues. This mechanism is biologically 
plausible as previous studies have shown that TGFα signaling affects both 
osteoclastogenesis and bone resorption (17, 18, 42, 53).  
In addition to the Egfr knockout mouse, Mmp13 and Mmp9 mutants display expanded 
hypertrophic zones, delayed vascularization, and delayed ossification (19, 41, 47). 
Mmp13 null mice were also found to have abnormal TRAP and PECAM-1 staining (19). 
Depending on the particular mutant studied, the abnormal growth plate phenotype was 
either persistent or resolved over time (19, 41). These data are relevant since our Tgfa 
null growth plate chondrocytes show decreased Mmp13 mRNA expression, in agreement 
with our previous osteoarthritis studies indicating that TGFα regulates Mmp13 
expression in articular chondrocytes (4, 5).  
Runx2 was the third gene showing reduced expression in Tgfa knockout cartilage. Runx2 
regulates terminal chondrocyte differentiation in the cartilage growth plate (20, 24) and 
both Mmp13 and the RANKL gene have been identified as downstream targets (11, 23). 
Thus, it seems plausible that Runx2 is the primary target of TGFα in chondrocytes and 
mediates the effects of this growth factor on MMP13, RANKL and the removal of 
hypertrophic cartilage. 
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Interestingly, when we treated embryonic tibia organ cultures with exogenous TGFα, we 
saw results that complemented our in vivo data. Specifically, we saw increases in both 
MMP13 and RANKL gene expression with treatment, suggesting once again that TGFα 
controls factors involved in the conversion of cartilage to bone. In the organ culture 
studies, we also observed decreased expression of early hypertrophic markers (p57 and 
ColX) and increased expression of late hypertrophic markers (Mmp9, Mmp13, and 
Mmp14). This could suggest that TGFα promotes transition from early hypertrophic 
chondrocytes to terminally differentiated cells. While ColX mRNA levels were not 
changed in newborn cartilage in vivo, this difference could be due to the stages of 
cartilage development analyzed in the two models or to differences between in vivo and 
in vitro models. 
Our knockout animals also show delayed secondary ossification and reduced staining of 
the vascular marker PECAM-1.  Both angiogenesis and matrix remodeling are crucial 
components of the terminal events of endochondral ossification (31), and EGFR signaling 
is known to have pro-angiogenic effects (2, 12, 35). TGFα specifically has been shown to 
increase the expression of vascular endothelial growth factor (VEGF) and other pro-
angiogenic factors (angiopoietin-2, G-CSF, HGF, IL-6, IL-8 and PDGF-BB) in 
mesenchymal stem cells (9). Studies have shown that inactivation of VEGF leads to 
decreased resorption of terminal chondrocytes, similar to what we observe in our mutant 
mice (13). When examining gene expression, however, we did not see a change in Vegfa 
mRNA. This leads us to believe that the observed delay in vascularization may either be 
due to a reduction in other angiogenic factors or posttranscriptional suppression of VEGF 
expression, or it may be secondary to reduced matrix remodeling caused by decreases in 
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MMP13 and RANKL gene expression. Furthermore, it is known that MMP14 plays a 
crucial role in the development of the secondary ossification centre (15). Previous studies 
in our lab have shown that Akt-1 knockout mice also experience delayed secondary 
ossification that appears to be mediated by MMP14 (43). We have also previously shown 
that Akt-1 is a downstream target of TGFα (5). Since our tibia organ cultures indicate 
that TGFα regulates MMP14 expression, this could be another mechanism by which Tgfa 
mutant mice experience delayed secondary ossification.  
The transient nature of the phenotype observed here might be explained by a potential 
compensatory mechanism since there are multiple EGFR ligands: amphiregulin (AR), 
betacellulin (BTC), EGF, epigen (EPGN), epiregulin (EREG), heparin-binding EGF-like 
growth factor (HBEGF), and TGFα (14). The indication for compensation is strong since 
mice lacking multiple ligands can still have subtle phenotypes. For example, triple 
knockouts lacking EGF, AR, and TGFα were found to be healthy and fertile, but had 
problems with mammary gland development (30). The roles of several EGFR ligands 
have been investigated in bone physiology through in vivo transgenic or knockout models 
(8, 36, 37), and most of these models show subtle skeletal effects (reviewed by Schneider 
et. al. (38)). We examined the gene expression of AR, EGF, and HBEGF in our Tgfa wild 
type and knockout mice through real-time PCR (Supplementary Figure 3.4). 
Interestingly, we saw no changes in the expression levels of these ligands. There are 
several possible explanations for this. Perhaps no single ligand is essential for 
compensation, but rather several ligands contribute with overlapping roles. Alternatively, 
regulation of the other EGFR ligands might occur post-transcriptionally. Finally, the 
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RNA we studied was from P0 mice (for technical reasons). Compensation may occur 
gradually or at a later time point.  
Another hypothesis to explain “catch-up growth” is delayed senescence of the growth 
plate (33, 34). Potentially, mice lacking TGFα could experience a temporary decreased 
growth rate that is later compensated by an increased duration of growth compared to 
control animals. Nevertheless, our data demonstrate a unique, non-redundant role of 
TGFα in endochondral ossification during early postnatal development. 
In conclusion, our data show that Tgfa knockout mice have a hitherto unrecognized 
growth plate phenotype. TGFα plays an important role in regulating endochondral 
ossification, osteoclast recruitment, and vascularization at the primary and secondary 
ossification center and appears to be the major ligand responsible for the observed roles 
of EGFR in endochondral ossification. 
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Supplementary Figure 3.1 Tgfa null mice show reduced TRAP staining along the 
cartilage/bone interface. P0 and P10 tissues were stained for the osteoclast (OC) marker 
tartrate resistant acid phosphatase (TRAP, dark purple). TRAP staining appears similar 
amongst various genotypes in P0 tissues and is located in discrete areas throughout the 
primary ossification centre (indicated by arrows). P10 knockout mice show reduced 
TRAP staining along the cartilage/bone interface when compared to their control 
littermates. WT= wild type, Het= heterozygous, KO= knockout (n=3). 
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Supplementary 3.1 Tgfa null mice show reduced TRAP staining along the cartilage/bone 
interface. 
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Supplementary Figure 3.2 The expression of many genes remains unchanged in 
TGFα-treated E15.5 tibia organ cultures. Tibiae were isolated from E15.5 CD1 mice, 
grown in culture and treated with a range of TGFα concentrations. After 6 days of 
treatment, RNA was isolated from the cartilage growth plates of these tibiae and real-time 
PCR was performed. No changes in the expression of Sox9, Acan, Col2a1, Atf3, Runx2, 
or Vegfa were observed (n=3-4/group, *: p<0.05). 
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Supplementary 3.2 The expression of many genes remains unchanged in TGFα-treated 
E15.5 tibia organ cultures. 
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Supplementary Figure 3.3 Tgfa null mice show less PECAM-1 staining than their 
littermates at the cartilage/bone interface.  P0, P10 and P21 long bones were stained 
with an anti-platelet endothelial cell adhesion molecule (PECAM-1) antibody in order to 
locate areas of vascularization. PECAM-1 expression appears similar in all P0 genotypes. 
P10 and P21 mutant mice show reduced PECAM-1 staining compared to their littermates 
along the cartilage/bone interface. WT= wild type, Het= heterozygous, KO= knockout 
(n=3). 
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Supplementary 3.3 Tgfa null mice express less PECAM-1 than their littermates at the 
cartilage/bone interface. 
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Supplementary Figure 3.4 Tgfa null mice do not show compensatory increases in 
transcript levels for the EGFR ligands Areg, Egf, and Hbegf. RNA was isolated from 
the growth plates of long bones of P0 mice and the expression of amphiregulin (Areg), 
epidermal growth factor (Egf), and heparin-binding EGF-like growth factor (Hbegf) was 
assessed by real-time PCR (A-C). There was no change in gene expression level for any 
of the EGFR ligands examined.  WT= wild type, KO = knockout (n=4/group, *: p<0.05). 
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Supplementary 3.4 Tgfa null mice do not show compensatory increases in transcript 
levels for the EGFR ligands Areg, Egf, and Hbegf. 
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Chapter 4  
4 TGFα null mice experience delayed progression of osteoarthritis in a surgical 
disease model 
Figures 4.2, 4.3, and 4.4 in this chapter will contribute to an original co-first author 
research article to be submitted for publication: 
Appleton CTG and Usmani SE, Pest MA, Pitelka V, Ulici V, Welch I, Hill TL, Mort J, 
and Beier F. The TGFα-CCL2 axis is a target for treatment of osteoarthritis. To be 
submitted to J Clin Invest, 2012. 
4.1 Abstract 
We have previously identified transforming growth factor alpha (TGFα) as a novel 
growth factor involved in cartilage degeneration during the disease process of 
osteoarthritis (OA). In vitro experiments show that TGFα treatment induces an OA-like 
phenotype in articular chondrocytes, characterized by inhibition of matrix synthesis and 
promotion of catabolic factor expression. In order to better understand and validate 
TGFα’s potential as a novel therapeutic target, we employed two in vivo models of the 
disease: a post-traumatic destabilization model and a spontaneous aging model. Ten-
week-old male Tgfa null mice and their heterozygous (control) littermates underwent 
surgery resulting in destabilization of the medial meniscus (DMM). Disease progression 
was assessed histologically at both seven and fourteen weeks post-surgery using the 
Osteoarthritis Research Society International (OARSI) scoring system. Six-month-old 
mice also underwent the same DMM procedure and were assessed at seven weeks post-
surgery. As well, spontaneous disease progression was analyzed in eighteen-month-old 
Tgfa null and heterozygous mice. We found that young, ten-week old knockout mice 
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were protected from OA progression at both seven and fourteen weeks post-surgery with 
statistically lower OARSI scores than their control littermates. When DMM was 
performed on six-month old animals however, no protection was seen. As well, no 
differences were observed between genotypes in the spontaneous again model.  
In conclusion, young Tgfa null mice are protected from OA progression in the DMM 
model, while older mice are not. In addition, Tgfa null mice are equally susceptible to 
spontaneous OA development. Thus, TGFα might be a valuable therapeutic target in 
post-traumatic forms of OA, however its role in idiopathic disease less clear.  
4.2 Introduction 
Osteoarthritis (OA) is the most prevalent joint disease and the most common cause of 
physical disability in western society (22, 39). Patients with OA experience joint pain and 
impaired function that may ultimately affect their ability to work and quality of life (38, 
43). Currently there are no treatment options that prevent, cure, or alter the disease 
course. Rather, therapeutic options are limited to symptom management (47). The 
financial consequences of managing OA are immense and relate to symptomatic 
treatment, joint replacement surgeries, and work lost to disability (9, 45).  Current 
estimates suggest that developed nations spend approximately one to two percent of their 
gross domestic product on OA and other rheumatic diseases (20). Furthermore, due to 
high rates of obesity and the aging population, the incidence of OA is only expected to 
rise in the coming years (22). Consequently the identification of good therapeutic targets 
for the development of disease modifying osteoarthritic drugs (DMOADs) is urgently 
needed.  
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The defining feature of OA is the degeneration of articular cartilage – the tissue that 
covers the ends of diarthrodial joints and enables their smooth, wear-resistant 
movements. Articular cartilage consists of an extracellular matrix rich in type II collagen 
and proteoglycans and is designed to absorb and disperse the forces experienced during 
joint loading (2). The extracellular matrix is sparsely populated by chondrocytes and 
these cells are responsible for both synthesizing the matrix and regulating its turnover 
(35). A number of growth factors, cytokines, and catabolic enzymes are involved in 
normal cartilage metabolism as well as in OA (33). As of yet however, none of the drugs 
aimed at these therapeutic targets has been successful in preventing, stopping or reversing 
the disease process in clinical trials (37).  
While the exact etiology of OA remains unclear, numerous risk factors have been 
identified (10, 49). Two of the most significant are joint injury and advanced age. It has 
been well established that a history of joint injury is a major risk factor for the 
development of OA (34). The causes of post-traumatic OA are vast but may involve 
intra-articular fractures, ligament tears, meniscal injuries, and even cartilage micro-
trauma from joint impact (3). In the United States, meniscal injuries represent the highest 
proportion of all intra-articular injuries (30). The menisci are crescent-shaped 
fibrocartilagenous tissues found between the femur and the tibia in the medial and lateral 
compartments of the knee joint (13). They help nourish and lubricate the articular 
cartilage, act as shock absorbers, and transmit over half of the total axial load applied to 
the knee joint (30). Studies have indicated that individuals with ligamentous or meniscal 
injuries increase their risk of developing OA by ten-fold, and meniscal damage is almost 
always present in patients with radiographic evidence of OA (3, 13). 
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In addition to injury, advancing age is another major risk factor for OA. It is unusual to 
find individuals over the age of sixty-five to seventy without radiographic evidence of 
OA (26). Several theories have been developed to describe the link between aging and 
OA, although there is still a lack of consensus in this area. Perhaps the simplest theory is 
that OA is a “wear and tear” disease brought about by repetitive loading and an 
accumulation of damage over time (1). This theory, however, does not explain why 
radiographic signs are completely absent in some elderly individuals (18, 27). Other 
theories relate to specific age-related changes observed in the articular cartilage matrix 
and chondrocytes themselves. For example, aged cartilage undergoes more collagen 
cross-linking, thus making it stiffer and perhaps more susceptible to mechanical injury 
(25). As well, decreases in aggrecan deposition are seen with age, thus altering the 
cartilage’s ability to deal with compressive forces (1). Aging also brings about various 
changes within the chondrocytes themselves including decreased responsiveness to 
anabolic cytokines such as transforming growth factor beta (TGFβ) and insulin-like 
growth factor-1 (IGF-1), and increased expression of reactive oxygen species (ROS) (26). 
Finally, remaining theories relate to aging and chondrocyte senescence, autophagy, and 
apoptosis (1, 25, 26). 
In order to better understand the molecular mechanisms involved in OA, our lab recently 
studied a rodent anterior cruciate ligament (ACL) transection model to identify genes 
involved in cartilage degeneration (6).  We identified transforming growth factor alpha 
(TGFα) as a novel growth factor involved in OA as its gene expression was increased in 
the disease state. Subsequent in vitro experiments showed that TGFα treatment resulted 
in a loss of chondrocyte phenotype: we observed decreases in anabolic factors including 
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type II collagen and aggrecan and increases in catabolic factors such as matrix 
metalloproteinase 13 (MMP13) (7). In this study, we wanted to determine the role of 
TGFα in the progression of OA in vivo and thus employed a post-traumatic OA model in 
the Tgfa knockout mouse. The OA model we used was the destabilization of medial 
meniscus (DMM) model which provides a relatively slowly progressing form of the 
disease that may have more relevance to the human disease course (16). We also 
observed spontaneous development of OA in aging Tgfa null mice. Since our previous 
studies suggested an overall catabolic effect of TGFα on chondrocytes, we hypothesized 
that Tgfa null mice would experience delayed OA progression in both the DMM model 
and in spontaneous disease development.  
4.3 Methods 
4.3.1 Transforming growth factor alpha null mice  
Tgfa null mice in a C57BL/6 genetic background were purchased from The Jackson 
Laboratory (Bar Harbor, Maine, USA) (31). All animals were bred and cared for in 
accordance with the University of Western Ontario’s Animal Care and Use Guidelines. 
DNA from digested ear and/or tail clippings was used in PCR genotyping. Two separate 
genotyping programs were used to amplify both the wild type Tgfa allele and the neo-
cassette found in the mutated alleles. Oligonucleotides TGFalphaA (5’-
GACTAGCCTGGGCTACACAGTG-3’) TGFalphaC (5’-
ACATGCTGGCTTCTCTTCCTGC-3’), NeoForward (5’-CTTGGGTGGAGAGGCT 
ATTC-3’) and NeoReverse (5’-AGGTGAGATGACAGGAGATC-3’) were purchased 
from Sigma-Aldrich (Oakville, Ont., Canada) and all other genotyping reagents were 
purchased from Applied Biosystems Incorporated (Foster City, CA, USA). All direct 
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comparisons were made between heterozygote and homozygote mutant siblings with at 
least four littermate pairs per time point per parameter examined. 
4.3.2 Destabilization of medial meniscus (DMM) model 
To study OA in Tgfa mutant animals, we employed the well-established surgical 
destabilization of medial meniscus (DMM) model (16). In this model, the medial 
meniscotibial ligament (which anchors the medial meniscus to the tibial plateau) is 
cleaved, resulting in joint destabilization. DMM was performed on the left knee joint of 
ten-week old male mice as previously described (44). Both Tgfa knockout mice and their 
heterozygous littermates were used in our studies. Heterozygous mice served as controls 
as previous studies have shown that Tgfa heterozygous mutants are phenotypically 
indistinguishable from their wild type littermates (31). Sham surgeries consisting of an 
incision to the left knee were also performed on both genotypes. A veterinarian and 
veterinarian technician with previous experience in the DMM procedure performed all 
surgeries. Mice were housed individually after surgeries. At seven and fourteen weeks 
post-surgery, mice were sacrificed and their knee joints were isolated for histology.  
To examine the effects of age and injury together, we also performed DMM surgeries as 
described above in six-month-old mice, and assessed disease progression at seven weeks 
post-surgery. 
4.3.3 Spontaneous osteoarthritis 
To study the spontaneous development of OA, male and female Tgfa null mice were 
housed with their heterozygous littermates until eighteen months of age. Several male 
pairs were separated throughout this time course due to fighting. At eighteen months of 
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age, mice were sacrificed and their knee, ankle and elbow joints were isolated and 
prepared for histology.  
4.3.4 Mouse tissue processing and histology 
Tissues were fixed overnight in 4% PFA, and decalcified in 5% EDTA in PBS. 
Decalcification was determined by physical end-point test. Tissues were then processed, 
embedded in paraffin wax, and 5 µm thick serial sections were cut in the sagittal plane 
starting from the medial joint compartment. Previous studies have shown that the most 
severe damage in both DMM and spontaneous models of OA occur in the medial 
compartment (28, 32). 
4.3.5 Safranin-O/fast green staining 
Sections were dewaxed in xylene and rehydrated through a series of graded ethanols 
ending in water. Tissues were then stained in 0.02% fast green for 25 minutes, dipped in 
1% glacial acetic acid, then stained in 0.1% safranin-O for 7 minutes. Tissues were 
dehydrated and mounted using a xylene-based mounting medium.  
4.3.6 Immunohistochemistry 
Immunohistochemistry was performed using primary antibodies against MMP13 
(Abcam, San Francisco, CA) and type II collagen neoepitopes exposed when type II 
collagen is cleaved by MMP13 (8).  Sections were first dewaxed in xylene, and 
rehydrated through a series of graded ethanol solutions ending in water.  Antigen retrieval 
was performed in 10 mM sodium citrate at 95oC for fifteen minutes.  Sections were 
blocked in 5% goat serum, then incubated with primary antibodies overnight.  Lastly, 
tissues were incubated in HRP-conjugated secondary antibody and visualized with the 
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substrate DAB (brown precipitate). All tissues were visualized using a Leica DM Series 
inverted fluorescence/light microscope (Leica Microsystems, Richmond Hill, ON, 
Canada). At least three pairs of animals were stained for each antibody and multiple 
sections were used for each trial. 
4.3.7 OARSI scoring for DMM 
For the DMM model, two blinded observers assigned a numerical grade and stage to each 
animal according to the Osteoarthritis Research Society International (OARSI) standards 
for OA histopathology (36). This was the same scoring system used in our previous rat 
studies (4, 5). Multiple sections were scored for each animal. One modification was made 
to the scoring system: a grade of 1 was assigned if the mouse cartilage had depleted 
safranin-O staining (representing depleted proteoglycan content) as this was determined 
to represent significant pathology, even in the absence of cartilage discontinuity. Scores 
were averaged for each group and statistical analysis was performed using a two-way 
ANOVA and Bonferroni post-tests.  
4.3.8 OARSI scoring for spontaneous OA 
One blinded observer assigned a semi-quantitative score to each animal based on the 
OARSI recommendations for histopathological assessment of OA in the mouse (17). 
Again, multiple sections were used for each animal. Since this scoring system is a 
variation of the one used to assess OA in the DMM model, no comparisons were made 
between the DMM animals and the eighteen month old mice. Scores were averaged for 
each group and statistical analysis was performed using a paired t-test.  
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4.4 Results 
4.4.1 Young adult Tgfa null mice experience delayed OA progression in a 
DMM model 
To examine the effects of Tgfa deficiency on post-traumatic OA in young adult mice, 
male 10 week-old heterozygote or homozygote mutant mice underwent DMM or sham 
surgery as depicted in Figure 4.1. Many disease features were apparent at the 7 week 
post-surgery time point in the DMM groups including chondrocyte clustering, 
hypertrophy, cell death, focal proteoglycan expression, and superficial zone fibrillation 
(Figure 4.2A). This indicated that DMM induced cartilage degeneration resembling OA 
pathology, as expected. The heterozygous DMM animals displayed more severe disease 
features including superficial zone delamination and lesions extending into the midzone 
(Figure 4.2A).  All sham animals retained relatively healthy cartilage with scores below 
6.0  (Figure 4.2A,B). At seven weeks post-surgery, the average OARSI score for 
heterozygous DMM mice was 13.7, while the score in the sham surgery group was 5.6 
(Figure 4.2B). Tgfa knockout mice that received the DMM surgery showed significantly 
lower OARSI scores (average of 6.4) than their heterozygous littermates but had similar 
scores to sham-operated heterozygote and homozygote mice (Figure 4.2B).  
We also examined molecular markers by immunohistochemistry to further validate our 
histological findings. Representative images show higher MMP13 staining in the articular 
cartilage of heterozygous DMM animals than in knockout DMM animals or in sham 
animals of either genotype (Figure 4.3A). Similarly, there appeared to be stronger type II 
collagen neoepitope staining in the cartilage of heterozygous DMM animals than in that 
of their knockout littermates or sham controls (Figure 4.3B).  
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Figure 4.1 A schematic representation of the post-traumatic and spontaneous aging 
models of OA used in this study. Ten-week old male Tgfa null and heterozygous mice 
underwent destabilization of medial meniscus (DMM) surgery. Two post-surgical time 
points were assessed with OARSI scoring: seven and fourteen weeks. Six-month-old Tgfa 
null and heterozygous mice also underwent DMM surgery and were assessed seven 
weeks post-surgery. Lastly, Tgfa null and heterozygous mice were housed for eighteen 
months with no surgical intervention, after which time spontaneous disease progression 
was assessed with OARSI scoring.  
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Figure 4.1 A schematic representation of the post-traumatic and spontaneous aging 
models of OA used in this study. 
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Figure 4.2 Tgfa knockout mice have lower OARSI scores than control littermates in 
a surgical model of OA. Ten-week-old Tgfa knockout mice and their heterozygous 
littermates received either surgery resulting in the destabilization of the medial meniscus 
(DMM) or sham surgery. At seven weeks post surgery, mice were sacrificed and their 
knee joints were prepared for histology. Tissues were stained with safranin-O and fast 
green (A) and then scored using the OARSI system for OA histopathology (B). Average 
OARSI scores +SEM are shown and indicate that Tgfa knockout mice have lower scores 
than OA heterozygous mice after DMM surgery (DMM groups n=5, sham groups n=4,  
*p<0.05). 
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Figure 4.2 Tgfa knockout mice have lower OARSI scores than control littermates in a 
surgical model of OA. 
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Figure 4.3 Tgfa knockout mice express less MMP13 and less type II collagen 
neoepitopes than control littermates at 7 weeks post-surgery. Histological sections 
were prepared from the knee joints of both Tgfa knockout and heterozygous mice at 
seven weeks post-surgery. Immunohistochemistry was performed with primary 
antibodies against MMP13 and type II collagen fragments. This was followed by 
secondary antibody incubation and visualization with the substrate DAB (brown 
precipitate).  Nuclei were counterstained with hematoxylin (blue). Representative images 
show that knockout animals express less MMP13 and type II collagen fragments than 
heterozygous controls. 
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Figure 4.3 Tgfa knockout mice express less MMP13 and less type II collagen 
neoepitopes than control littermates at 7 weeks post surgery. 
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Similar results were seen when mice were analyzed fourteen weeks after surgery; 
heterozygous DMM animals had significantly higher scores (17.3) than knockout DMM 
animals (10.2) (Figure 4.4B). Many more DMM animals displayed advanced disease 
features such as superficial zone delamination and lesions extending into the midzone 
(Figure 4.4A), and some heterozygous animals displayed lesions extending to the 
calcified cartilage. Scores for both DMM groups were higher than at the seven week time 
point, indicating that the disease had progressed, while both sham groups had scores 
similar to those of the earlier time point (Figure 4.4B).  
4.4.2 6-month-old Tgfa null mice are not protected from OA progression in a 
DMM model 
These results suggested that loss of TGFα signaling protects from post-traumatic OA in 
young adults, a finding of significant impact for the human population because of the 
high number of sports-related injuries in this age group. However, humans joint injuries 
can also occur at later ages, thus combining two OA risk factors (aging and injury). To 
address this point, we performed DMM and sham surgery on six-month-old mice. OA 
progression was more advanced than when surgery was performed on younger mice 
(Figure 4.5A). Both Tgfa knockout mice and their heterozygous littermates had average 
OARSI scores of 17.1 when assessed at seven weeks post-surgery (Figure 4.5B). A 
number of disease features were evident including proteoglycan loss, superficial zone 
delamination and erosion of midzone cartilage (Figure 4.5A). In addition to the disease 
features mentioned above, some six moth old tissues revealed denudation to the calcified 
zone. Tgfa null mice were no longer protected from developing OA, since the knockout 
mice had scores and histopathological features similar to those of the heterozygous mice 
(Figure 4.5B).  
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Figure 4.4 Tgfa knockout mice still show resistance to developing OA at 14 weeks 
post-surgery. 10 week-old Tgfa knockout mice and their heterozygous littermates 
received DMM surgery or sham surgery. At fourteen weeks post surgery, mice were 
sacrificed and their knee joints were prepared for histology. Tissues were stained with 
safranin-O and fast green (A) and then scored using the OARSI system for OA 
histopathology (B). DMM knockout animals still displayed lower OARSI scores than 
their heterozygous control littermates at this time point (DMM groups n=6, sham groups 
n=4, *p<0.05). 
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Figure 4.4 Tgfa knockout mice still show resistance to developing OA at 14 weeks post 
surgery. 
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Figure 4.5 There is no difference in disease progression between knockout and 
control animals after DMM surgery in middle-aged mice. Six-month-old Tgfa 
knockout and heterozygous mice received DMM or sham surgery. At seven weeks post 
surgery, these mice were sacrificed and their knee joints were isolated and prepared for 
OARSI scoring. Average OARSI scores +SEM are shown and indicate that DMM 
knockout and heterozygous mice are equally susceptible to developing OA in this model 
(sham groups n=4, DMM Het n=6, DMM KO n= 8, *p<0.05).  
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Figure 4.5 There is no difference in disease progression between knockout and control 
animals after DMM surgery in middle-aged mice. 
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4.4.3 Tgfa null mice are not protected from developing spontaneous OA 
To address a potential role of TGFα in aging-associated OA, the knee, elbow, and ankle 
joints of eighteen-month-old mice were examined for spontaneous OA. Female mice 
were essentially completely protected from developing OA (data not shown). This 
finding has been well established in the literature and is attributed to difference in sex 
hormones (29). The knee joints of male mice showed the most advanced disease of the 
joints examined, revealing areas of proteoglycan loss, some areas of superficial zone 
delamination, and some loss of the midzone cartilage. Regardless of the genotype, 
however, articular cartilage remained largely intact, and areas of cartilage loss were focal 
in nature (Figure 4.6A). The elbow and the ankle cartilage for both Tgfa null and 
heterozygous mice was relatively healthy and showed only initial signs of OA, 
particularly proteoglycan loss (Figure 4.6B,C). Essentially all of the tissues examined 
from the elbow and the ankle had an intact articular cartilage surface, free of fibrillations 
and fissures (Figure 4.6B,C). 
4.5 Discussion 
Previously, our lab identified TGFα as a novel growth factor involved in the 
degeneration of articular cartilage (15, 16). In this study, we examined the role of TGFα 
in the progression of OA in vivo through the use of the Tgfa null mouse. We analyzed 
two separate models of OA: the post-traumatic DMM model as well as a spontaneous 
model of OA in aging mice. When young adult, ten-week old Tgfa null mice received 
DMM surgery, they were protected from developing OA at both post-surgical time points 
examined. While they still showed signs of degeneration, particularly at the later time  
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Figure 4.6 Tgfa knockout and heterozygous mice are equally susceptible to 
developing OA in an aging disease model. Male Tgfa knockout and heterozygous mice 
were housed until eighteen months of age. Animals were then sacrificed, and their knee 
(A), elbow (B) and ankle (C) joints were prepared for histology. Tissues were stained 
with safranin-O and fast green and scored using the OARSI recommendations for 
histopathological assessment of OA in the mouse. There were no differences in OARSI 
scores between genotypes for any of the joints examined (knee n=7, elbow n=4, ankle 
n=4, p<0.05).  
 
147 
 
 
 
Figure 4.6 Tgfa knockout and heterozygous mice are equally susceptible to developing 
OA in an aging disease model. 
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point (14 weeks after surgery), disease progression was histologically less severe than 
that of control littermates. These data support our hypothesis, which is that in the absence 
of TGFα, mice are protected from OA development in a post-traumatic model. Our 
hypothesis was based on previous in vitro experiments that showed TGFα induced an 
OA-like phenotype in articular chondrocytes (7), as well as our findings of upregulation 
of Tgfa gene expression in a rat model of post-traumatic OA (4, 6). Specifically, TGFα 
caused a decrease in expression of Sox9, aggrecan, and type II collagen mRNA, and 
increased the expression of catabolic factors such as MMP13 (7). Thus by eliminating 
TGFα, we expected that we could reduce these overall catabolic events. 
Contrary to our hypothesis however, the Tgfa null mice were not protected from 
developing OA in our spontaneous aging model or when DMM was performed in older 
mice. As mentioned previously, several changes occur in aging cartilage that could 
potentially make it more susceptible to injury, such as a more heavily cross-linked 
extracellular matrix, a loss in aggrecan content, and chondrocytes that are less responsive 
to anabolic factors (1). Furthermore, studies have shown that in the C56 BL/6 mouse 
articular cartilage thickness decreases with age, chondrocyte death increases, and the 
overall number of chondrocytes decreases as well (32).  These changes within the tissue 
provide one potential explanation for why our older Tgfa null mice were more susceptible 
to or less protected from OA development. In addition to the articular cartilage itself, 
changes within the broader context of the joint are seen with aging. A recent study by 
Loeser et al. looked at the differences in gene expression within the entire joint in young 
and old mice receiving either sham or DMM surgery (28). In this particular study, twelve 
week old mice were used for the young group and twelve month old mice were used for 
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the aged group (28). Interestingly, many genes were found to be dysregulated between 
the young and aged groups post DMM surgery, as well as between the young and old 
sham-operated mice (28). This study clearly illustrates baseline differences in gene 
expression between joint tissues of young and old mice as well as differences in gene 
expression changes in response joint injury (28). Novel genes, including some related to 
muscle development and immune function, were identified thus highlighting the fact that 
tissues beyond the articular cartilage itself are likely important in the disease process 
(28). Since we did not specifically study other joint tissues (synovial membrane, 
subchondral bone, or surrounding muscles), it is possible that changes in these structures 
affected the overall function of the joint with age.  
A study by Goekoop et al in 2005 examined a group of ninety-year-olds living without 
OA and identified several protective factors including male sex, a normal body mass 
index (BMI), and the absence of a family history of osteoarthritis (18). Obesity is a well-
established risk factor for osteoarthritis, however its role in OA extends beyond 
mechanical effects, and a vast body of research is now focused on the link between fat 
metabolism and OA (15, 41). Furthermore, as people age, muscle mass generally declines 
and fat content increases (12).  The animals in our studies were weighed at the time of 
surgery and sacrifice, however no differences were observed between the two genotypes 
(data not shown).  While BMI and fat composition were not assessed quantitatively, older 
animals of both genotypes were observed to have more fat within their tissues upon 
dissection. Thus, perhaps the lack of protection seen in older Tgfa knockout mice could 
be attributed to changes relating to fat composition and metabolism.   
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There is additional evidence to suggest that TGFα and its downstream signaling pathway 
might be a good therapeutic target for OA therapy.  TGFα is a member of the epidermal 
growth factor (EGF) family and signals through the EGF receptor (EGFR) (11, 23, 24). 
Recent studies have shown that mutant mice with enhanced EGFR signaling develop 
early, spontaneous degenerative disease in multiple joints the including knee, ankle, and 
temporomandibular joints (21, 50). These mice have a mutation in mitogen-inducible 
gene 6 (MIG6), also known as RALT or Gene 33 (50). MIG6 is a cytoplasmic protein 
that negatively regulates EGFR signaling through several mechanisms, including 
inhibition of the receptor kinase domains and receptor internalization and degradation 
(14, 19, 46, 48). These mutant mice have classical arthritic features such as loss of 
proteoglycan content, degradation of articular cartilage, formation of subchondral cysts, 
synovial hyperplasia, osteophyte formation, and abnormal calcification (21, 50). These 
studies suggest that increased EGFR signaling is sufficient to trigger spontaneous disease 
progression in vivo and consequently one might infer that blocking this signaling could 
prevent or delay disease progression. One difference between the MIG6 studies and our 
study is that in these models signaling from all EGFR ligands is inhibited while we 
specifically targeted TGFα. Thus, compensation by other EGF family members is 
another possible explanation for the lack of protection from OA in aging Tgfa null mice. 
As well, we have recently described a transient developmental bone phenotype in our 
Tgfa null mice that appears to resolve by ten weeks of age (the age that DMM surgeries 
are performed in this study) (42). However, we cannot be certain that the effects of this 
developmental phenotype, which include delayed osteoclast recruitment and decreased 
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MMP13 and RANKL (receptor activator of nuclear factor kappa B ligand) gene 
expression, do not have an effect on the outcome of our OA studies (42). 
Our current results, however, suggest that targeting TGFα and its receptor might be 
beneficial in a subset of patients, potentially younger patients who have experienced a 
joint injury. It is possible that TGFα plays an important role post-trauma. We first 
identified TGFα as a growth factor involved in cartilage degeneration in microarray 
studies from another post-traumatic model of OA, namely the rat ACL transection/partial 
meniscectomy model (6). Our previous in vitro studies showed that in addition to the loss 
of chondrocyte phenotype, TGFα had an effect on chondrocyte proliferation both in 
primary articular chondrocyte cell culture and in an articular cartilage organ culture 
system (7). In the organ culture system, proliferation was evident based on the presence 
of chondroyte clusters, a well-established sign of early OA, believed to represent an 
attempt at cartilage repair (7, 40). Thus it is possible that TGFα is produced locally 
within the joint in response to injury, but lacks to ability to successfully repair cartilage.  
Our collaborators also examined TGFα mRNA in human cartilage collected at the time 
of joint replacement (7). Five of twelve arthritic samples expressed markedly increased 
TGFα mRNA levels, thus again suggesting that the growth factor plays an important role 
in a subset of patients (7).  
Overall it appears that TGFα plays an important role in post-traumatic OA progression. 
Other factors, such as age however, also contribute to disease severity and progression. It 
may be important to take factors such as age and mechanism of joint injury into account 
when selecting patient for clinical trials for the development of DMOADs.  
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Chapter 5  
5 Discussion 
5.1 Overview 
The overall objective of my thesis was to gain a better understanding of the role of 
transforming growth factor alpha (TGFα) in cartilage biology, both in the cartilage 
growth plate during endochondral bone development and in degenerating articular 
cartilage during the disease state of osteoarthritis (OA). My laboratory first became 
interested in TGFα after my colleagues performed microarray studies on articular 
cartilage isolated from a surgical rat model of OA (6, 7). TGFα mRNA levels were 
elevated almost 4-fold in the OA animals compared controls (6). The laboratory decided 
to pursue this growth factor further since its role in normal cartilage biology was not fully 
understood and since it had not previously been implicated in OA initiation or 
progression. Initial in vitro investigations showed that TGFα had a profound effect on the 
chondrocyte phenotype: TGFα treatment caused changes in chondrocyte morphology, 
induced proliferation, and shifted synthesis away from anabolic factor expression towards 
that of catabolic factor expression (8). The next logical step was to investigate possible 
downstream pathways that might regulate TGFα-induced effects on the chondrocyte 
phenotype.  
The first study in my thesis investigates the link between TGFα and the endothelin 
receptor A (ET(A)R) signaling system. Just like TGFα, the gene for ET(A)R denoted as 
Ednra, was upregulated in the original rat model of OA (6). There is also a body of 
literature implicating ET(A)R in both OA and normal chondrocyte aging (30-34, 40, 45, 
46, 51). Since age is one of the most common risk factors for OA, I decided that this 
157 
 
would be a good downstream candidate target to focus on. Furthermore, ET(A)R is 
known to interact with the receptor through which TGFα signals, the epidermal growth 
factor receptor (EGFR), in other diseases such as cancer (10, 37). I subsequently 
performed in vitro experiments with primary chondrocyte cell cultures and osteochondral 
organ culture explants. I found that TGFα induced ET(A)R expression at both the mRNA 
and protein level. However, inhibiting ET(A)R with a non-specific ET(A/B)R antagonist 
only partially blocked the TGFα effects in our explant model. Thus while ET(A)R 
appears to be a downstream target of TGFα, the signaling pathways affected by this 
growth factor are clearly more complex.   
Next I wanted to examine TGFα function in the skeleton using an in vivo system. 
Therefore the third and fourth chapters of this thesis involve the Tgfa knockout mouse 
previously characterized by Mann et al. (41). The major phenotype reported in this mouse 
is the presence of a wavy coat due to the misalignment of hair follicles (41). No mention 
of bone or cartilage abnormalities is made. Previous in vitro literature, on the other hand, 
does suggest a role for TGFα in bone development and turnover. Studies indicate that 
TGFα has a negative effect on chondrogenesis of limb bud mesenchymal cells (14, 23, 
64). As well, research has shown that TGFα stimulates bone resorption and inhibits bone 
formation in vitro (25, 26). The role of TGFα during endochondral bone development has 
not been explicitly examined however, and this led me to my second major study.  
I examined the cartilage growth plates of Tgfa wildtype, heterozygous, and null mice 
over a variety of time points ranging from newborn to ten weeks of age. Interestingly, 
Tgfa null mice were found to have a transient growth plate phenotype characterized by an 
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enlarged hypertrophic zone and decreased numbers of osteoclasts at the cartilage/bone 
interface. Analysis of gene expression revealed that these mice also express less matrix 
metalloproteinase 13 (MMP13) as well as less receptor activator of nuclear factor kappa-
B ligand (RANKL) mRNA than their heterozygous and wild type littermates. RANKL is 
an important activator of osteoclastogenesis and chondrocyte-produced RANKL has been 
shown to stimulate osteoclast formation (35, 57). MMP13 also plays an important role in 
extracellular matrix breakdown during endochondral bone formation, and is required for 
normal vascularization and subsequent bone remodeling (27, 56). Thus I demonstrated a 
previously unrecognized growth plate phenotype in the Tgfa knockout mouse and 
reported TGFα’s regulatory role in the transition from cartilage to bone.  
Lastly, I wanted to examine the role of TGFα in the disease state of osteoarthritis in vivo. 
I used the well-established destabilization of medial meniscus model (DMM) to represent 
a slowly progressing model of post-traumatic OA (19). Furthermore, I examined 
spontaneous disease progression in aging animals. Due to the overall catabolic effect of 
TGFα in articular chondrocytes and cartilage explants in vitro, I hypothesized that Tgfa 
null mice would be protected from OA progression in both the injury and aging models.  
I found that young knockout mice were protected in the DMM model, however aging 
knockout mice developing spontaneous disease as well as older knockout mice receiving 
DMM surgery were not protected from OA progression. This study demonstrates that 
TGFα may be an important therapeutic target in post-traumatic forms of OA, however its 
role may not be as significant when other risk factors such as age come into play. This 
study also reminds us that OA is a complex multifactorial disease and that treatments 
may need to be specific to the main etiological risk factors involved.  
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Overall, these data demonstrate an important role for TGFα both in the conversion of 
cartilage to bone during endochondral ossification, and in cartilage degeneration in 
osteoarthritis. A common thread between development and disease, is that both of these 
mechanisms appear to be driven in part through the production of catabolic factors such 
as MMP13.  
5.2 Contributions and Significance of Findings 
5.2.1 Contributions to the Field of Skeletal Biology 
In this thesis, I characterize for the first time the growth plate phenotype of TGFα null 
mice. Prior to these studies, the role of TGFα in the cartilage growth plate had not been 
explicitly investigated. As mentioned above however, previous work did highlight 
TGFα’s negative effect on chondrogenesis and its stimulatory effect on 
osteoclastogenesis (14, 23, 25, 26, 64). I describe the transient growth plate phenotype of 
Tgfa null mice that includes shorter tibiae and humeri, an enlarged hypertrophic zone and 
overall growth plate length, delayed primary and secondary ossification, and reduced 
osteoclast staining at the cartilage/bone junction. To complement the decrease in 
osteoclasts, I also demonstrate a decrease in Mmp13 and Rankl gene expression. The 
phenotype seen is very similar to that of the Efgr knockout mouse (61). Since these mice 
do not survive long after birth, they were consequently studied during embryonic 
development only. Their growth plate phenotype, however, is very similar to that seen in 
my studies and is characterized by delayed primary ossification, an enlarged hypertrophic 
zone, and decreased osteoclast recruitment (61). This study examined the inactivation of 
the EGF receptor and thus the identity of the ligand or ligands involved remained 
unknown. The bone phenotypes of other EGFR ligand knockout mice have been 
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characterized, including amphiregulin (AREG) and betacellulin (BTC) (52). Neither of 
these models however, has reported a growth plate phenotype as seen in the Egfr 
knockout mouse. Thus it is likely that TGFα is one of the main ligands responsible for 
the roles of EGFR during endochondral ossification. In addition, my studies provide 
mechanistic insights into the observed phenotype, namely through the reduced expression 
of MMP13 and RANKL in cartilage of Tgfa null mice. 
My collaborators recently published a study exploring the inactivation of EGFR at post-
natal time points in the rat through the use of an EGFR specific inhibitor, gefitinib (66). 
Their study complements the Tgfa knockout model in that the gefitinib-treated rats 
developed an expanded cartilage growth plate with an accumulation of hypertrophic cells, 
and had decreased osteoclasts at the osteochondral junction (66). The rats also expressed 
less Rankl and Mmp13 than untreated animals (66). To determine whether these effects 
were due to primary effects on the growth plate, my collaborators also created cartilage-
specific Egfr knockout mice using the Col2a1-promoter to drive Cre recombinase 
expression (66).  Again, similar changes in the growth plate were observed, thus 
revealing that EGFR inactivation directly affects the cartilage growth plate. The overlap 
observed between the TGFα knockout mouse and models of EGFR inactivation further 
suggests that TGFα is the main mediator of EGFR effects in the cartilage growth plate.  
In addition to these findings, I implicate TGFα in the development of the secondary 
ossification centre for the first time. Tgfa null mice show delay in secondary ossification 
when compared to their control littermates. When I performed immunohistochemistry 
(IHC) in the secondary ossification centre with an antibody specific for the blood vessel 
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marker platelet endothelial cell adhesion molecule 1 (PECAM-1), I saw reduced levels of 
staining in the mutant animals. Thus in addition to its role in the primary ossification 
centre, I have demonstrated a role for TGFα in secondary ossification development.  
Lastly, through in vivo embryonic tibia organ culture studies, I show that TGFα affects 
genes related to chondrocyte hypertrophy. Specifically, TGFα decreases expression of 
early hypertrophic markers including p57 and ColX, and increases the expression of late 
hypertrophic markers including the Mmp9, Mmp13, and Mmp14. These results suggest a 
novel role for TGFα in promoting the transition from early hypertrophic to terminally 
differentiated chondrocytes. Collectively these data contribute to the growing 
understanding of molecular mechanisms controlling the organization and regulation of 
the cartilage growth plate. They also give us insight into how TGFα might contribute to 
cartilage pathology in osteoarthritis, namely through catabolic factor expression and 
potentially through other mechanisms such as chondrocyte hypertrophy.  
5.2.2 Contributions to Field of Osteoarthritis  
I demonstrate that ET(A)R is a downstream target of TGFα. Furthermore I demonstrate 
this in two different species (rat and mouse) and in tissues of varying ages (embryonic, 
newborn, and four to five month old tissues). My in vitro experiments show that TGFα 
upregulates ET(A)R in articular chondrocytes at both the mRNA and protein level. This 
is consistent with previous work, demonstrating that a number of growth factors and 
cytokines including EGF are able to induce ET(A)R expression in articular chondrocytes 
(46). Inhibiting endothelin signaling with a non-specific ET(A/B)R inhibitor however, 
only partially blocks TGFα catabolic effects in articular cartilage, namely the expression 
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of MMP13 and subsequent breakdown of type II collagen. Thus there must be other 
signaling pathways downstream of TGFα capable of mediating its OA-like phenotype. 
Additional work done in my lab demonstrates that various pathways are responsible for 
mediating TGFα effects in articular chondrocytes. For example, RhoA/ROCK has been 
shown to mediate TGFα -induced morphologic changes in chondrocytes, in agreement 
with previous studies demonstrating important roles of this pathway in chondrogenesis 
(60, 62). The MEK/ERK pathway mediates the downregulation of anabolic gene 
expression by TGFα, again fitting with known roles of this pathway in chondrocytes (11, 
55). Both the Rho/ROCK and MEK/ ERK pathway also regulate type II collagen 
cleavage and aggrecan breakdown in articular cartilage (9). Thus while TGFα is capable 
of inducing ET(A)R expression in articular chondrocytes, this is only one signaling 
pathway of many involved in the induction of an OA-like phenotype. 
In addition, I also show an increase in inducible nitric oxide synthase (iNOS) staining in 
IHCs from the TGFα- treated organ culture studies. To my knowledge, this is the first 
time that TGFα has been shown to effect parameters of nitric oxide (NO) metabolism in 
articular chondrocytes. This is significant as the increase in iNOS may contribute to NO 
production and potentially serve as another mechanism through which TGFα carries out 
its catabolic effects (5, 47, 58). Recently, a study by Kaufman et al complemented my 
ET(A)R studies nicely (29). This group demonstrated that inhibition of the ET(A)R with 
a specific inhibitor (BQ-123) in a surgical model of OA prevented disease progression. A 
similar model of OA was used (rat ACL transection) as in my laboratory’s original 
studies (6, 7).  
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My in vivo models of OA also provide novel information to the field. I demonstrate that 
young adult Tgfa null mice are protected from developing OA in a DMM model of the 
disease, both at seven and fourteen weeks post-surgery. Through this in vivo model, I 
have validated TGFα as a potential therapeutic target for the development of a disease 
modifying osteoarthritic drug (DMOAD). Experts in the field support the use of in vivo 
surgical disease models to validate potential therapeutic OA targets (17). For example, 
DMM surgery was performed in the ADAMTS-5 (a disintegrin and metalloproteinase 
with thrombospondin motifs) knockout mouse, and observations of delayed disease 
progression now make it one of the most attractive targets for DMOAD development (18, 
48).  
Prior to the microarray studies, TGFα had not been implicated in the disease process. 
Previous research did however, report the presence of TGFα in the synovial fluid and 
synovial membranes of arthritic patients with higher levels observed in individuals with 
rheumatoid arthritis (RA) than in those with OA (22, 36). TGFα has also been detected in 
control synovium and synovial fluid, suggesting a normal physiological role within the 
joint (22). Evidence does exist however, for the involvement of EGFR in OA 
development. Recent studies involving mice with mutations in mitogen-inducible gene 6 
(MIG6) have reported spontaneous degenerative joint disease in these animals (67). 
MIG6 (also known as RALT or Gene 33) is a cytoplasmic protein that negatively 
regulates EGFR signaling by several mechanisms (16, 21, 63, 65). Homozygous null 
mutants of the Mig6 allele develop early degenerative disease in the knee, ankle, and 
temporomandibular joints (28, 67). As well, the Mig6 null joints show classical arthritic 
features including depletion of proteoglycans, degradation of articular cartilage, 
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formation of subchondral cysts, synovial hyperplasia, osteophyte formation, and 
abnormal calcification (28, 67). These studies illustrate that enhanced EGFR signaling is 
sufficient to trigger spontaneous disease progression in vivo and thus complement my 
knockout studies, in which decreased EGFR ligand is protective.  
My studies also reveal that the protection from OA is not universal in all osteoarthritic 
models. In the aging models (spontaneous OA development and DMM surgery 
performed in older mice) the Tgfa knockout mice are no longer protected from disease 
progression, and they develop OA that is histologically indistinguishable from control 
mice. Age is a major risk factor for the development of OA, and specifically with 
meniscal injuries, it has been shown that the tempo of disease progression varies with age 
(44, 50). Patients who sustain a meniscal injury between the ages of seventeen and thirty 
develop radiologic signs of OA on average after fifteen years, while patients who sustain 
the same injury over the age of thirty develop signs of OA only five years later (50). Our 
data fit with this clinical picture as the aging mice show more aggressive lesions post-
surgery, and all aging mice regardless of genotype are susceptible to disease progression. 
These data also contribute to the theory that OA is a heterogeneous disease based on 
specific etiological risk factors (i.e. obesity, aging, injury) and that DMOADs should be 
developed with these sub-phenotypes of OA in mind (12). In the case of TGFα, the 
evidence thus far suggests that it might be an important therapeutic target in post-
traumatic cases of OA in young individuals. 
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5.3 Limitations of Research  
5.3.1 Limitations of In Vitro Models  
I acknowledge that these studies have several limiting factors. Firstly, my in vitro 
experiments are clearly limited by their ability to recapitulate the in vivo environment. 
For the ET(A)R studies I used both primary chondrocyte cultures and osteochondral 
explant cultures. The primary chondrocyte cultures were isolated from the distal femoral 
condyles of neonatal rats and plated in monolayer culture as previously described (53). 
The benefit of this culture system is that a large number of cells can be isolated at once; 
chondrocyte isolation would be far more challenging from mature articular cartilage with 
sparse cellular density. However, the major drawback is that these cells are very young, 
and as previous stated, differences in gene expression, responses to growth factors, and 
receptor profiles are seen with aging chondrocytes (38, 45, 46). This culture system may 
not have been the best choice for my ET(A)R studies as the receptor density is known to 
increase significantly with aging chondrocytes (45, 46). Furthermore, monolayer cultures 
lack interaction with an extracellular matrix. Consequently, cell surface receptors such as 
integrins that would normally interact with the matrix, likely have altered signaling in this 
context (20).  
The osteochondral explants address some of these limitations (i.e. they are derived from 
adult animals and retain an intact extracellular matrix), but they still lack the influence of 
mechanical forces. Chondrocytes are known to response to various forces through 
integrin receptors, stretch-activated calcium ion channels, and deformation of the 
chondrocyte cytoskeleton (2, 4, 13, 20). Lastly, these in vitro models lacked the context 
of the joint as a unit. It is well established that OA is a disease affecting the entire joint 
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including the articular cartilage, synovial membrane, joint capsule, and subchondral bone 
(3, 24). By examining effects on articular chondrocytes or cartilage alone we lose 
potentially important cross-talk between these tissues. Future in vivo studies using 
pharmacological or genetic manipulation of the ET(A)R signaling system would 
complement our studies, but as outlined, some of these have been performed by others 
recently (29). 
The non-specific ET(A/B)R inhibitor Bosentan that was used in my studies also provides 
some concerns. Bosentan is a dual endothelin receptor A/B antagonist which is clinically 
used for the treatment of pulmonary arterial hypertension (43). We chose to use this drug 
since it has already been approved for use clinically. However, the antagonist is not 
selective for ET(A)R and thus it is possible that some of the effects we saw in 
chondrocyte cell culture and organ culture were due to inactivation of ET(B)R and its 
downstream pathways. Use of receptor-specific antagonists such as BQ-123 would be 
one potential future application. 
5.3.2 Limitations of In Vivo Models 
In my growth plate studies, RNA was isolated from newborn (P0) mice since cartilage is 
expansive and easily accessible at this stage. It is difficult to distinguish the growth plate 
cartilage from what will become the articular cartilage at this stage since the secondary 
ossification centre (which divides these two regions) has not yet developed. While the 
mutant phenotype is predominantly present in the hypertrophic zone of the growth plate, I 
decided to take all cartilage from P0 tibia since it is plausible that factors regulating this 
phenotype may come from other areas of the growth plate or other chondrocytes in 
general. It is possible that some areas of the growth plate might have been missed during 
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isolation, especially some of the cartilage adjacent to the mineralized zone. Furthermore, 
it is possible that other tissues such as perichondrium were isolated along with the 
cartilage. I did my best to remove all excess tissues and collect the complete growth 
plate, however it is possible that some of the gene changes we observed were in part due 
to additional tissues.  
I used full body Tgfa knockout mice in my experiments, in which the Tgfa allele was 
disrupted by the insertion of a neomycin cassette (41). Since I did not use a tissue-
specific knockout model, I cannot be completely confident that the developmental 
phenotype I have characterized is due to direct effects of the absence TGFα of on the 
growth plate. Rather, it is possible that these effects are mediated by some other systemic 
factors influenced by the null mutation. My collaborators however, have created a 
cartilage-specific Egfr knockout mouse that has a similar phenotype to the Tgfa null 
mice, thus suggesting that my observations may indeed be due to direct effects (66). 
Furthermore, while I describe a transient developmental phenotype in these mice that 
resolves by ten weeks of age, I cannot be absolutely certain that this phenotype does not 
in some way persist or affect the OA studies. My conclusion that TGFα is a novel 
therapeutic DMOAD target, assumes that the developmental phenotype does not in some 
way affect OA susceptibility in our knockout animals. In other words, unlike a drug that 
could be administered to patients at the time of joint injury, our mice have always had 
their mutation, and this fact may affect the clinical relevance of our study.  
My collaborators (Qin and colleagues, University of Pennsylvania) performed micro CT 
analysis on aging animals and found that the Tgfa null skeleton appears to lose both 
cortical area and trabecular volume over time (data not shown).  I need to perform more 
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studies to correctly interpret these results, however it is evident that there are still some 
effects of the Tgfa mutation even in mice older than ten weeks of age.  
The DMM surgery provides a mild model of post-traumatic OA (19). It is relevant as 
meniscal injuries are almost always seen with radiographic signs of OA, and as the 
meniscus is the most commonly injured intra-articular tissue (15, 39). I also employed an 
aging model of OA by analyzing spontaneous joint disease. While I limited my analysis 
to these two models, there are numerous additional risk factors that contribute to OA 
including obesity, female gender, and repetitive mechanical loading. From this thesis, my 
interpretations are limited to the role of TGFα in post-traumatic OA and aging as I did 
not take these other factors into account. Currently however, some of my colleagues are 
investigating the effects of a high fat diet on joint pathology in various genetically 
modified mice, including the Tgfa mutants. 
5.4 Future Directions 
Several possible future projects could be explored based on the results of this thesis. 
Firstly, to confirm both the Tgfa null growth plate phenotype and the results from our OA 
models, it would be useful to create a cartilage-specific Tgfa knockout mouse using the 
Cre-loxP system with Cre recombinase expressed under control of the Col2a1 promoter, 
as our laboratory has done for other genes (54, 59). In addition, it would be beneficial to 
examine multiple joint tissues including the subchondral bone, synovium, and synovial 
fluid. By examining the entire joint, one may gain a better understanding of how these 
tissues interact and signal to each other throughout disease progression.  Furthermore, I 
could add gait analysis to these studies to assess joint function. Thus far I have been 
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focusing on cartilage damage as the main endpoint. However structural changes alone are 
not sufficient for a clinical diagnosis of the OA.  
It might also be worthwhile to create an inducible, tissue-specific ET(A)R knockout 
mouse. Full body ET(A)R knockout mice do not survive long after birth due to 
respiratory distress and they also display craniofacial abnormalities (1). While another 
group has already demonstrated that OA progression can be delayed in an ACL 
transection model of OA with ET(A)R inhibition, it might be of value to determine 
whether knocking out this receptor later in life prevents spontaneous disease progression.  
This would be particularly interesting since ET(A)R expression in chondrocytes appears 
to increase with age (45, 46). 
Lastly, it would be very interesting to explore the role of TGFα in other forms of joint 
disease such as RA. As previously mentioned, TGFα has been identified in synovial fluid 
and synovial membranes of both OA and RA patients, and higher levels were actually 
observed in individuals with RA (22, 36). Furthermore, studies have shown that bone 
destruction in RA may be mediated by osteoclasts, and that chondrocyte-produced 
RANKL may contribute to the activation of cells and subsequent juxta-articular bone loss 
(42, 49). These findings suggest that TGFα could affect RA and possibly OA through 
effects on osteoclasts. 
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Appendices 
Appendix A: Animal Protocols 
 
AUP Number: 2007-003-02 
PI Name: Beier, Frank 
AUP Title: Tgfα/egfr Signaling In Osteoarthritis 
Official Notice of Animal Use Subcommittee (AUS) Approval: Your new Animal Use 
Protocol (AUP) entitled "Tgfα/egfr Signaling In Osteoarthritis" has been APPROVED by 
the Animal Use Subcommittee of the University Council on Animal Care. This approval, 
although valid for four years, and is subject to annual Protocol Renewal.2007-003-02::5 
1. This AUP number must be indicated when ordering animals for this project.  
2. Animals for other projects may not be ordered under this AUP number.  
3. Purchases of animals other than through this system must be cleared through the 
ACVS office. Health certificates will be required.  
The holder of this Animal Use Protocol is responsible to ensure that all associated safety 
components (biosafety, radiation safety, general laboratory safety) comply with 
institutional safety standards and have received all necessary approvals. Please consult 
directly with your institutional safety officers. 
Submitted by: Copeman, Laura  
on behalf of the Animal Use Subcommittee 
University Council on Animal Care  
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AUP Number: 2007-045-06 
PI Name: Beier, Frank 
AUP Title: Regulation Of Endochondral Bone Growth By Hormones 
Official Notice of Animal Use Subcommittee (AUS) Approval: Your new Animal Use Protocol (AUP) 
entitled "Regulation Of Endochondral Bone Growth By Hormones 
 
" has been APPROVED by the Animal Use Subcommittee of the University Council on Animal Care. This 
approval, although valid for four years, and is subject to annual Protocol Renewal.2007-045-06::5 
1. This AUP number must be indicated when ordering animals for this project. 
2. Animals for other projects may not be ordered under this AUP number. 
3. Purchases of animals other than through this system must be cleared through the ACVS office. 
Health certificates will be required. 
The holder of this Animal Use Protocol is responsible to ensure that all associated safety components 
(biosafety, radiation safety, general laboratory safety) comply with institutional safety standards and have 
received all necessary approvals. Please consult directly with your institutional safety officers. 
Submitted by: Copeman, Laura  
on behalf of the Animal Use Subcommittee 
University Council on Animal Care  
 
 
 
 
 
 
 
 
 
 
178 
 
Appendix B: Permission to Include Published Manuscripts 
 
179 
 
 
 
 
 
180 
 
Curriculum Vitae 
 
Shirine Elizabeth Usmani 
 
Education 
 
2010- present The University of Western Ontario, Schulich School of Medicine and 
Dentistry, London, ON 
 MD Candidate (Class of 2014) 
 
2007- present  The University of Western Ontario, Department of Physiology and 
Pharmacology, London, ON 
PhD Candidate  
 
2003-2007 University of Western Ontario, Department of Physiology and 
Pharmacology, London, ON 
Bachelor of Medical Sciences, Scholar’s Elective Program/Honors 
Specialization in Physiology and Pharmacology 
 
Publications 
Appleton CT, Usmani SE, Bernier SM, Aigner T, and Beier F. Transforming growth 
factor alpha suppression of articular chondrocyte phenotype and Sox9 expression in a rat 
model of osteoarthritis. Arthritis Rheum 56: 3693-3705, 2007. 
Appleton CT, Usmani SE, Mort JS, and Beier F. Rho/ROCK and MEK/ERK activation 
by transforming growth factor-alpha induces articular cartilage degradation. Lab Invest 
90: 20-30, 2010. 
Usmani SE, Appleton CT, and Beier F. Transforming growth factor-alpha induces 
endothelin receptor A expression in osteoarthritis. J Orthop Res, 2012. 
Usmani SE, Pest MA, Kim G, Ohora SN, Qin L, and Beier F. Transforming growth 
factor alpha controls the transition from hypertrophic cartilage to bone during 
endochondral bone growth. Bone 51: 131-141, 2012. 
 
Awards and Scholarships 
 
• Canadian Institutes of Health Research (CIHR) Frederick Banting and Charles 
Best Canada Graduate Scholarships Doctoral Award, 2009-2012 
• Ontario Graduate Scholarship (OGS), 2009-2010 
• Ontario Graduate Scholarship in Science and Technology (OGSST), 2008-2009 
• Canadian Arthritis Network (CAN) Trainee Award, 2007-2010 
• Wilensky Prize in Physiology 2010 
• Gordon Mogenson Graduate Scholarship in Physiology 2010  
• Dr. Suzanne Bernier Memorial Award in Skeletal Biology, 2009 
181 
 
• Graduate Student Teaching Award Nominee, The University of Western Ontario, 
2009, 2010 
• Margaret Moffat Research Day Best Poster Award, Physiology Category, 2010 
• Canadian Society for Clinical Investigation Young Investigators Forum, Best 
Poster Award, 2009 
• Margaret Moffat Research Day Best Poster Award, Physiology and 
Endocrinology Category 2009 
Note: Not all scholarships were accepted as some were awarded at the same time. 
 
 
Teaching Experience 
 
2008-2010 Teaching Assistant for Physiology 2130 (Human Physiology)  
2008-2009 Training of two 4th year students in Physiology 4980E (Thesis Course) 
2008  Teaching Assistant for Physiology 9550 (Molecular Techniques) 
2007-2008 Teaching Assistant for Physiology 314A (Cellular Physiology)  
 
 
Scientific Meetings Attended 
  
• Osteoarthritis Research Society International World Congress on Osteoarthritis 
(Barcelona, 2012) 
• Osteoarthritis Research Society International World Congress on Osteoarthritis 
(San Diego, 2011) 
• Osteoarthritis Research Society International World Congress on Osteoarthritis 
(Belgium, 2010) 
• Canadian Arthritis Network Annual Scientific Meeting (Vancouver, 2009) 
• Canadian Society for Clinical Investigation (CSCI)/Clinician Investigator Trainee 
Association of Canada (CITAC) Annual Conference and Young Investigators 
Forum (Ottawa, 2009) 
• Osteoarthritis Research Society International World Congress on Osteoarthritis 
(Montreal, 2009) 
• Canadian Arthritis Network Annual Scientific Meeting (Toronto, 2008) 
• Osteoarthritis Research Society International World Congress on Osteoarthritis 
(Rome, 2008) 
• American Physician Scientists Association Meeting (Chicago, 2008) 
• Great Lakes Mammalian Developmental Biology Meeting (Toronto, 2008) 
• Canadian Arthritis Network Annual Scientific Meeting (Halifax, 2007) 
